r_datetime,url,title,citation,snippet
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation.,Elife. 2020 Sep 21;9:e60742. doi: 10.7554/eLife.60742.,"UIMs function by interacting with the heat shock protein, Hsc70-4, whose reduction diminishes ataxin-3 toxicity in a UIM-dependent manner. Hsc70-4 also enhances pathogenicity of other polyglutamine proteins. Our studies provide a unique insight into the impac …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Methyl donor supply to heat stress-challenged polymorphonuclear leukocytes from lactating Holstein cows enhances 1-carbon metabolism, immune response, and cytoprotective gene network abundance.",J Dairy Sci. 2020 Sep 17:S0022-0302(20)30722-0. doi: 10.3168/jds.2020-18638. Online ahead of print.,"Compared with PMN receiving 0 μg of Chol/mL, heat-stressed PMN supplemented with Chol at 400 or 800 μg/mL had greater fold-change in abundance of CBS, CSAD, GSS, GSR, and GPX1. ...Both Chol and Met supply enhanced the cytoprotective characteristics of PMN through upregulat …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,RP11-462C24.1 suppresses proliferation and invasion of colorectal carcinoma cells by regulating HSP70 through PI3K/AKT signaling pathway.,Hum Cell. 2020 Sep 18. doi: 10.1007/s13577-020-00426-7. Online ahead of print.,"From the results, we found that RP11-462C24.1 was significantly decreased in CRC tumor tissues and the CRC cell lines, which were most significant in SW480 and HT-29 cell lines; moreover, transient overexpression of RP11-462C24.1 suppressed the growth and migration while promoted …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Small heat shock protein Hsp67Bc plays a significant role in Drosophila melanogaster cold-stress tolerance.,J Exp Biol. 2020 Sep 17:jeb.219592. doi: 10.1242/jeb.219592. Online ahead of print.,"Hsp67Bc in Drosophila melanogaster is a member of the small heat shock protein family, the main function of which is to prevent the aggregation of misfolded or damaged proteins. ...In addition, the deletion in the Hsp67Bc gene caused more prominent up-regulat …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"LsHSP70 is induced by high temperature to interact with calmodulin, leading to higher bolting resistance in lettuce.",Sci Rep. 2020 Sep 16;10(1):15155. doi: 10.1038/s41598-020-72443-3.,"High temperatures have significant impacts on heat-tolerant bolting in lettuce. In this study, it was found that high temperatures could facilitate the accumulation of GA in lettuce to induce bolting, with higher expression levels of two heat shock protein ge …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Znonps AND GENE EXPRESSION IN BROILERS Effects of Zinc Oxide Nanoparticles on Regulatory Appetite and Heat Stress Protein Genes in Broiler Chickens Subjected to Heat Stress.,J Anim Sci. 2020 Sep 16:skaa300. doi: 10.1093/jas/skaa300. Online ahead of print.,"Our findings revealed that dietary ZnONPs altered the gene expression of cholecystokinin (ileum), HSP 70 (jejunum and ileum) and HSP 90 (duodenum, jejunum, and ileum). ...More studies are required to elucidate its complex physiological and biochemical functio …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Immune Responses of Asian Seabass Lates calcarifer to Dietary Glycyrrhiza uralensis.,Animals (Basel). 2020 Sep 11;10(9):E1629. doi: 10.3390/ani10091629.,"To understand the impacts of dietary Glycyrrhiza uralensis on the immune responses of Lates calcarifer, the expression of immune-related genes including crp, c-3, c-4, mtor, mlst-8, eif4e, hsp-70, hsp-90, il-8il-8, il-10, tgfβ1, tnf, ifn-γ1, and mxf in L. cal …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms.,Cancers (Basel). 2020 Sep 11;12(9):E2592. doi: 10.3390/cancers12092592.,"Heat shock proteins (HSPs) are cytoprotective stress-response chaperones involved in protein homeostasis and in many critical pathways, including inflammation. ...These HSPs include HSP70, HSP90 (chaperoning JAK2) and both HSP110 and HSP27, which are k …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Effects of chronic nitrate exposure on the intestinal morphology, immune status, barrier function, and microbiota of juvenile turbot (Scophthalmus maximus).",Ecotoxicol Environ Saf. 2020 Sep 15;207:111287. doi: 10.1016/j.ecoenv.2020.111287. Online ahead of print.,"Additionally, the expression of HSP70 and HSP90 heat-shock proteins, toll-like receptor-3 (TLR-3), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) significantly increased (P < 0.05), whereas that of transforming growth factor-β (TGF-β), …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis.,Oncoimmunology. 2020 May 13;9(1):1756130. doi: 10.1080/2162402X.2020.1756130.,"Heat shock proteins (HSPs) harbor great potential as cancer biomarkers and HSP inhibitors approach clinical cancer therapy. METHODS: To explore HSP pathophysiology, we assessed sera (immunoassays) and tissues (immunohistochemistry) of TETs (and …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,SEM and qRT-PCR revealed quercetin inhibits morphogenesis of Aspergillus flavus conidia via modulating calcineurin-Crz1 signalling pathway.,Mycology. 2020 Jan 13;11(2):118-125. doi: 10.1080/21501203.2020.1711826.,Significant inhibition of conidial swelling of A. flavus in comparison to control was observed at 4 and 7 h Quantitative real-time PCR for genes from calcium signalling pathway and heat-shock proteins family showed up-regulation of heat shock ( …
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Manipulation of Quercetin and Melatonin in the Down-Regulation of HIF-1α, HSP-70 and VEGF Pathways in Rat's Kidneys Induced by Hypoxic Stress.",Dose Response. 2020 Aug 28;18(3):1559325820949797. doi: 10.1177/1559325820949797. eCollection 2020 Jul-Sep.,"Over protein-expression of vascular endothelial growth factor and heat shock, protein-70 and mRNA of HIF-1α were also observed. ...HIF-1α and HSP-70 are implicated in the induction of hypoxia and its treatment...."
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Overexpression of miR-144-3p alleviates polycystic ovaries syndrome through targeting expression of HSP-70.,Gene Ther. 2020 Sep 11. doi: 10.1038/s41434-020-00191-0. Online ahead of print.,"Moreover, HSP-70 was a direct target of miR-144-3p. Furthermore, increased expression of HSP-70 rescued the effects of miR-144-3p on ovarian granulosa cell growth and apoptosis. In addition, knockdown of HSP-70 alleviated endocrine disord …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Hepatotoxic effect of lead and hepatoprotective effect of Hydrilla verticillata on hepatic transcriptional and physiological response in edible fish Labeo rohita.,Drug Chem Toxicol. 2020 Sep 9:1-8. doi: 10.1080/01480545.2020.1815762. Online ahead of print.,"The metal binding stress proteins, heat shock proteins (Hsp60 & Hsp70) and metallothionein were also upregulated due to lead toxicity. ...Administration of supplementary feed to the lead intoxicated protective group significantly decreased t …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.,Front Immunol. 2020 Aug 13;11:1816. doi: 10.3389/fimmu.2020.01816. eCollection 2020.,"We evaluated IVIgG alone, and with a Heat shock protein (HSP)-90 or proteasome inhibitor, using multiple myeloma and mantle cell lymphoma (MCL) cells in vitro, and with the proteasome inhibitor bortezomib in vivo. ...Preparations of IVIgG were found to contai …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Biological Responses to Cadmium Stress in Liverwort Conocephalum conicum (Marchantiales).,Int J Mol Sci. 2020 Sep 4;21(18):E6485. doi: 10.3390/ijms21186485.,"Oxidative damage (production and localization of reactive oxygen species) and related response mechanisms (activity of antioxidant enzymes), and induction of Heat Shock Protein 70 expression, have been studied in the toxi-tolerant liverwort Conocephalum conic …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Addition of exogenous proteins detected in oviductal secretions to in vitro culture medium does not improve the efficiency of in vitro fertilization in pigs.,Theriogenology. 2020 Aug 27;157:490-497. doi: 10.1016/j.theriogenology.2020.08.017. Online ahead of print.,"This work was designed to study whether HSP70-1A, HSP90α, ezrin or PDI4, proteins previously identified in porcine oviductal secretions, have a role in zona pellucida (ZP) resistance to enzymatic digestion, in vitro fertilization (IVF) and sperm viability. ...Sperm …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,[Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis].,Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jul 30;40(7):1062-1065. doi: 10.12122/j.issn.1673-4254.2020.07.23.,"These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of IPF (such as TOLLIP rs3750920 g …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Participation of Hsp70 and Hsp90α Heat Shock Proteins in Stress Response in the Course of Type 1 Diabetes Mellitus.,Dokl Biol Sci. 2020 Jul;493(1):124-127. doi: 10.1134/S0012496620040079. Epub 2020 Sep 7.,"The role of two heat shock proteins, Hsp70 and Hsp90α, on stress response in mice with severe diabetes mellitus induced by a high dose of alloxan (500 mg/kg body weight), as well as in RIN-m5F β cells cultured in the presence of cytokines (IL-1 and TNF …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Cellular and functional adaptation to thermal stress in ovarian granulosa cells in mammals.,J Therm Biol. 2020 Aug;92:102688. doi: 10.1016/j.jtherbio.2020.102688. Epub 2020 Aug 12.,"Additionally, thermal stress induces upregulation of thermal shock proteins, such as HSP70 and HSP90. This review provides an update on the influence of thermal stress on GCs of mammals. Discussions include impacts to steroidogenesis (estradiol and progestero …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.",Oncogene. 2020 Sep 14. doi: 10.1038/s41388-020-01454-1. Online ahead of print.,"Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.,Hemasphere. 2020 Jul 21;4(4):e424. doi: 10.1097/HS9.0000000000000424. eCollection 2020 Aug.,"Newer JAK inhibitors that are distinguished from ruxolitinib and fedratinib by their ability to improve anemia (eg, momelotinib) or safety and efficacy in severely thrombocytopenic patients (eg, pacritinib) are in phase 3 clinical trials. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.",Curr Hematol Malig Rep. 2020 Aug 11. doi: 10.1007/s11899-020-00596-z. Online ahead of print.,"Fedratinib, momelotinib, and pacritinib are three newer-generation JAK inhibitors being prospectively evaluated and we will discuss their roles in the treatment of myeloproliferative neoplasms. ...Pacritinib has been studied in myelofibrosis patients with significan …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019.,Crit Care Explor. 2020 Jun 15;2(6):e0138. doi: 10.1097/CCE.0000000000000138. eCollection 2020 Jun.,"Cytokine release syndrome mediated by interleukin-6 is a critical driver of coronavirus disease 2019 mortality. Herein, we review and discuss key immunologic effects of direct interleukin-6 blockade, downstream nonselective Janus kinase inhibition, and selective Jan …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.,Ther Adv Hematol. 2020 May 15;11:2040620720925201. doi: 10.1177/2040620720925201. eCollection 2020.,"This medication was found to be effective in reduction of symptom burden and spleen size; however, the median duration of response is about 3 years. ...Additional JAK-i have been developed over the last 8 years, including fedratinib, momelotinib, and pacritinib …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.,Br J Haematol. 2020 May 11. doi: 10.1111/bjh.16665. Online ahead of print.,Relapse rates are high even with the integration of first-generation FMS-like tyrosine kinase 3 (FLT3) inhibitors in pre- and post-transplant regimes and as maintenance in FLT3-mutated AML. ...
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Management of Myelofibrosis: from Diagnosis to New Target Therapies.,Curr Treat Options Oncol. 2020 Apr 30;21(6):46. doi: 10.1007/s11864-020-00734-y.,"Median survival ranges from approximately 3.5 to 5.5 years; while the most frequent cause of death is the evolution to acute myeloid leukemia, also other conditions such as progression without transformation, complications due to cytopenias including i …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo.,Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa020. doi: 10.1093/noajnl/vdaa020. Epub 2020 Feb 18.,RESULTS: We show that afatinib and pacritinib decreased BTSC growth and sphere-forming capacity in vitro. Combinations of the 2 drugs were synergistic and abrogated the activation of STAT3 signaling observed upon EGFR inhibition in vitro and in vivo. ...Combined inh …
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Management of myelofibrosis after ruxolitinib failure.,Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20.,"Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitinib after 2- …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application.",Carcinogenesis. 2020 Jul 14;41(7):993-1004. doi: 10.1093/carcin/bgz178.,"An in vitro drug screening found that AT9283 and Pacritinib could be effective JAK2 inhibitors, which was consistent with the in vivo xenograft response. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Novel treatment strategies for myeloproliferative neoplasms.,Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176.,"Several newer JAK inhibitors (fedratinib, pacritinib, momelotinib) have shown activity in phase 3 trials in patients with myelofibrosis but have, for various reasons, not yet received regulatory approval; all these agents, however, remain in active clinical developm …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.",PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019.,"To provide further translational insights into clinical outcomes, we compared phenotypic biomarker profiles of ruxolitinib, fedratinib, momelotinib, and pacritinib in the BioMAP® Diversity PLUS panel of 12 human primary cell systems designed to recapitulate key aspe …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages.,J Clin Med. 2019 Jul 2;8(7):959. doi: 10.3390/jcm8070959.,We found that GBM-associated macrophages (GAMs) secreted exosomes which were enriched with oncomiR-21. Coculture of GAMs (and GAM-derived exosomes) and GBM cell lines increased GBM cells' resistance against temozolomide (TMZ) by upregulating the prosurvival gene programmed …
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.",Invest New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17.,"We determined that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations. ...Pacritinib was administered at a dose of 100 mg or 200 mg twice daily following a 3 + 3 dose-escalation in combi …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,New Concepts of Treatment for Patients with Myelofibrosis.,Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y.,"Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. ...Pacritinib, a non-myelosuppressive JAK2-selective inhibitor, is currently in a dose-ranging …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib in Patients with Myelofibrosis-Reply.,JAMA Oncol. 2018 Dec 1;4(12):1787. doi: 10.1001/jamaoncol.2018.4842.,
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib in Patients With Myelofibrosis.,JAMA Oncol. 2018 Dec 1;4(12):1786-1787. doi: 10.1001/jamaoncol.2018.4830.,
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.,Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058. eCollection 2018 Sep 7.,"Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib to treat myelofibrosis patients with thrombocytopenia.,Expert Rev Hematol. 2018 Sep;11(9):707-714. doi: 10.1080/17474086.2018.1500456. Epub 2018 Jul 19.,"Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis. ...Safety concerns pertaining to cardiovascular events and bleeding that arose in an early analysis of PERSIST-2 were likely related to the …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.,J Exp Pharmacol. 2018 May 9;10:9-17. doi: 10.2147/JEP.S150729. eCollection 2018.,"Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients. ...METH …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.,Proc Natl Acad Sci U S A. 2020 Sep 21:201919766. doi: 10.1073/pnas.1919766117. Online ahead of print.,"GC cells treated with midostaurin or bosutinib significantly suppressed migration in vitro and in zebrafish models. Immunohistochemical analyses of PHF8, PKCα, and PTEN showed a positive correlation between PHF8 and PKCα but negative correlations between PHF8 and PTEN and …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07014-7. Online ahead of print.,"We enumerate the practical issues faced in the use of midostaurin like antifungal prophylaxis, dosage of concomitant chemotherapy agents as well as available data on sequencing of the FLT3 inhibitors. Lastly we provide our perspective of the future directions for FLT3 inhi …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.06989-X. Online ahead of print.,"First-generation multi-kinase inhibitors (sorafenib, midostaurin, lestaurtinib) are characterized by a broad-spectrum of drug targets, whereas secondgeneration inhibitors (quizartinib, crenolanib, gilteritinib) show more potent and specific FLT3 inhibition, and are thereby …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.,Eur J Haematol. 2020 Sep 18. doi: 10.1111/ejh.13518. Online ahead of print.,"In multivariate analysis, midostaurin use and allo-SCT in CR1 were the most significant factors affecting overall survival (OS). ...In low-AR patients, the midostaurin effect was much less prominent. CONCLUSIONS: Our results demonstrate benefits of midostaurin …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,"Indole alkaloids, synthetic dimers and hybrids with potential in vivo anticancer activity.",Curr Top Med Chem. 2020 Sep 8. doi: 10.2174/1568026620666200908162311. Online ahead of print.,"Vinblastine, midostaurin, and anlotinib as the representative of indole alkaloids, synthetic dimers and hybrids respectively have already been clinically applied to treat many types of cancers, demonstrating indole alkaloids, synthetic dimers and hybrids are useful scaffol …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,FLT3 Inhibition in Acute Myeloid Leukemia.,Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S5-S6. doi: 10.1016/S2152-2650(20)30441-9.,The approved FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve survival in AML with FLT3 mutations. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis.,Cancers (Basel). 2020 Aug 19;12(9):E2341. doi: 10.3390/cancers12092341.,"Anti-myeloma activity of FLT3 inhibitors (midostaurin, gilteritinib) was tested in vitro on MM cell lines and primary MM cells by (3)H-tymidine incorporation assays or flow cytometry. ..."
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.,Leuk Lymphoma. 2020 Aug 19:1-8. doi: 10.1080/10428194.2020.1805109. Online ahead of print.,RADIUS-X (NCT02624570) was an expanded access program providing access to midostaurin during regulatory review and extending the understanding of the safety and tolerability of midostaurin. ...Midostaurin demonstrated a manageable safety profile and was assoc …
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.,Oncotarget. 2020 Jul 21;11(29):2807-2818. doi: 10.18632/oncotarget.27656. eCollection 2020 Jul 21.,"Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy [1, 2]. ...We observed a correlation between FLT3-ITD mutations and midostaurin sensitivity as expected and observed KRAS …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.,Cancer Chemother Pharmacol. 2020 Sep;86(3):325-337. doi: 10.1007/s00280-020-04114-z. Epub 2020 Aug 3.,"The effect of FLT3i (quizartinib, midostaurin, sorafenib) on cell proliferation and cell cycle kinetics was assessed in AML cell lines with differing FLT3 status; HEL (negligible expression of wild-type FLT3), EOL1 (wild-type FLT3), MV4-11 (FLT3-ITD resulting in constituti …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Management of Acute Myeloid Leukemia (AML) in Older Patients.,Curr Oncol Rep. 2020 Jul 28;22(10):103. doi: 10.1007/s11912-020-00964-1.,"We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. ..."
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.,Biomedicines. 2020 Jul 24;8(8):245. doi: 10.3390/biomedicines8080245.,"FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib show excellent response rates in patients with FLT3-mutated AML, but its duration of response may not be sufficient yet. ...On-target mutations (i.e., FLT3-TKD) such as D835Y keep the TK domain in its active …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,The Time Has Come for Targeted Therapies for AML: Lights and Shadows.,Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24.,"These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibito …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.,Ann Hematol. 2020 Sep;99(9):1989-2007. doi: 10.1007/s00277-020-04186-0. Epub 2020 Jul 18.,"In this systematic review, we analyze DDIs of glasdegib, venetoclax, midostaurin, quizartinib, gilteritinib, enasidenib, and ivosidenib. CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and t …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.,Haematologica. 2020 Jul 2:haematol.2019.231944. doi: 10.3324/haematol.2019.231944. Online ahead of print.,CD44-induced VLA-4 activation could be inhibited by the Src family kinase inhibitor PP2 and the multikinase inhibitor midostaurin. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.,Cancer Treat Rev. 2020 Aug;88:102026. doi: 10.1016/j.ctrv.2020.102026. Epub 2020 May 16.,"Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton's tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CL …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.,Br J Haematol. 2020 Aug;190(3):467-470. doi: 10.1111/bjh.16800. Epub 2020 Jun 21.,
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Fentanyl inhibits acute myeloid leukemia differentiated cells and committed progenitors via opioid receptor-independent suppression of Ras and STAT5 pathways.,Fundam Clin Pharmacol. 2020 Jun 21. doi: 10.1111/fcp.12581. Online ahead of print.,Fentanyl significantly augmented the efficacy of cytarabine but not midostaurin in AML differentiated cells and committed progenitors. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.,Cancers (Basel). 2020 Jun 14;12(6):1574. doi: 10.3390/cancers12061574.,"The FLT3-ITD mutation is targetable with approved FLT3 small molecule inhibitors, including midostaurin and gilteritinib. However, outside of patients receiving allogeneic transplant, most patients fail to respond or relapse, suggesting alternative approaches of therapy wi …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.,Ann Hematol. 2020 Jul;99(7):1429-1440. doi: 10.1007/s00277-020-04107-1. Epub 2020 Jun 8.,Midostaurin is a novel agent for FLT3-TKD/-ITD(mut)-acute myeloid leukemia (AML) and metabolized via cytochrome P450 3A4 (CYP3A4). ...Concomitant administration of both drugs leads to elevated midostaurin exposure. Both drugs improve overall survival at low numbers …
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,First report of Godronia cassandrae as a major cranberry fruit rot pathogen in Eastern Canada.,Plant Dis. 2020 Sep 15. doi: 10.1094/PDIS-06-20-1193-PDN. Online ahead of print.,"., 2003), it was supposed to amplify with the molecular tool developed from the strain DAOM C216021 (AAFC, Ottawa, ON) identified in 1993 on Vaccinium angustifolium as G. cassandrae. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Comparative analysis of cadmium uptake and distribution in contrasting canadian flax cultivars.,BMC Res Notes. 2020 Sep 7;13(1):424. doi: 10.1186/s13104-020-05265-1.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Fungal endophyte diversity in table grape berries.,Can J Microbiol. 2020 Aug 11. doi: 10.1139/cjm-2020-0293. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,In vitro ruminal fermentation of Fenugreek (Trigonella foenum-graecum L.) produced less methane than that of alfalfa (Medicago sativa).,Asian-Australas J Anim Sci. 2020 May 12. doi: 10.5713/ajas.20.0114. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Editorial: Why Livestock Genomics for Developing Countries Offers Opportunities for Success.,Front Genet. 2020 Jun 26;11:626. doi: 10.3389/fgene.2020.00626. eCollection 2020.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Mapping of Major Fusarium Head Blight Resistance from Canadian Wheat cv. AAC Tenacious.,Int J Mol Sci. 2020 Jun 24;21(12):4497. doi: 10.3390/ijms21124497.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Destigmatizing Carbohydrate with Food Labeling: The Use of Non-Mandatory Labelling to Highlight Quality Carbohydrate Foods.,Nutrients. 2020 Jun 9;12(6):1725. doi: 10.3390/nu12061725.,"The existing labelling frameworks discussed here align with established measures of carbohydrate quality, such as 1. dietary fibre nutrient content claims and associated dietary fibre-based health claims; 2. the presence of whole carbohydrate foods and ingredients that are …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Local White Matter Fiber Clustering Differentiates Parkinson's Disease Diagnoses.,Neuroscience. 2020 May 21;435:146-160. doi: 10.1016/j.neuroscience.2020.03.049. Epub 2020 Apr 6.,Automatically annotated fibre clustering (AAFC) is a novel clustering method based on diffusion magnetic resonance imaging (dMRI) tractography that enables highly robust reconstruction of white matter tracts that are composed of corresponding clusters. ...We applied AAF …
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Effect of fructose and its epimers on postprandial carbohydrate metabolism: A systematic review and meta-analysis.,Clin Nutr. 2020 Mar 10:S0261-5614(20)30104-7. doi: 10.1016/j.clnu.2020.03.002. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Structural genome analysis in cultivated potato taxa.,Theor Appl Genet. 2020 Mar;133(3):951-966. doi: 10.1007/s00122-019-03519-6. Epub 2019 Dec 31.,"Further, the auxin-induced SAUR genes (involved in abiotic stress), disease resistance genes and the 2-oxoglutarate/Fe(II)-dependent oxygenase superfamily proteins, among others, had increased copy numbers in these sequenced genomes relative to the references...."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Establishment and validation of cell pools using primary muscle cells derived from satellite cells of pig skeletal muscle.,In Vitro Cell Dev Biol Anim. 2020 Mar;56(3):193-199. doi: 10.1007/s11626-019-00428-2. Epub 2019 Dec 23.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Spontaneous Mutations in the Nitrate Reductase Gene napC Drive the Emergence of Eco-friendly Low-N(2)O-Emitting Alfalfa Rhizobia in Regions with Different Climates.,Microb Ecol. 2020 May;79(4):1044-1053. doi: 10.1007/s00248-019-01473-w. Epub 2019 Dec 11.,"., Sinorhizobium meliloti B399), which are closely related to the denitrifier model strain Sinorhizobium meliloti 1021, have conserved nitrate, nitrite, and nitric oxide reductases associated with the production of the greenhouse gas nitrous oxide (N(2)O) from nitrate but …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Discerning the effects of phosphate status on the metabolism of hybrid poplar.,Tree Physiol. 2020 Feb 20;40(2):158-169. doi: 10.1093/treephys/tpz114.,"During senescence, the hybrid poplar Tristis had higher sulfate and organic acid resorption, while hybrid willow, AAFC-5, had higher phosphate resorption proficiencies, suggesting differing anion remobilization mechanisms. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,New Syrphidae (Diptera) of North-eastern North America.,Biodivers Data J. 2019 Sep 3;7:e36673. doi: 10.3897/BDJ.7.e36673. eCollection 2019.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Patterns and Cardiometabolic Outcomes in Diabetes: A Summary of Systematic Reviews and Meta-Analyses.,Nutrients. 2019 Sep 13;11(9):2209. doi: 10.3390/nu11092209.,"The Portfolio dietary pattern improved cardiometabolic risk factors and reduced estimated 10-year coronary heart disease (CHD) risk by 13% (-1.34% (95%CI, -2.19 to -0.49)). ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Identification of Primary Antimicrobial Resistance Drivers in Agricultural Nontyphoidal Salmonella enterica Serovars by Using Machine Learning.,mSystems. 2019 Aug 6;4(4):e00211-19. doi: 10.1128/mSystems.00211-19.,"With our research representing one of the largest studies of a diverse set of NTS isolates from broiler chicken, we can thus confirm that the AmpC-like CMY-2 β-lactamase is a primary driver of β-lactam resistance and that the phosphotransferases APH(6)-Id and APH(3″-Ib) ar …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Dueling KRASG12C Inhibitors Achieve Responses.,Cancer Discov. 2020 Jan;10(1):10. doi: 10.1158/2159-8290.CD-ND2019-012. Epub 2019 Dec 10.,"Clinical trials of two KRAS(G12C) inhibitors, MRTX849 and AMG 510, have shown robust efficacy in phase I trials including patients with non-small cell lung cancer. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: Assessment of Causal Relations.,Nutrients. 2019 Jun 25;11(6):1436. doi: 10.3390/nu11061436.,"While dietary factors are important modifiable risk factors for type 2 diabetes (T2D), the causal role of carbohydrate quality in nutrition remains controversial. ...Here, the results of our recent meta-analyses of prospective cohort studies of 4 to 26-y follow-up are inte …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Soil respiration response to alterations in precipitation and nitrogen addition in a desert steppe in northern China.,Sci Total Environ. 2019 Oct 20;688:231-242. doi: 10.1016/j.scitotenv.2019.05.419. Epub 2019 Jun 1.,"There was a significant increase in soil respiration under N addition at 11.5%. Statistical assessment of their interactions demonstrated that N supplementation strengthened the stimulation of soil respiration under increased precipitation, whereas decreased precipitation …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: A Systematic Review and Updated Meta-Analyses of Prospective Cohort Studies.,Nutrients. 2019 Jun 5;11(6):1280. doi: 10.3390/nu11061280.,"Published meta-analyses indicate significant but inconsistent incident type-2 diabetes(T2D)-dietary glycemic index (GI) and glycemic load (GL) risk ratios or risk relations (RR). ...Thecombined T2D-GI RR was 1.27 (1.15-1.40) (p < 0.001, n = 10 studies) per 10 units GI, …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Effects of wild blueberry (Vaccinium angustifolium) pomace feeding on gut microbiota and blood metabolites in free-range pastured broiler chickens.,Poult Sci. 2019 Sep 1;98(9):3739-3755. doi: 10.3382/ps/pez062.,"Slow-growing broiler chickens were reared on pasture up to 64 D for sampling after 2 wk of treatment during brooding with 0, 1, and 2% LBBP in feed. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Pharmacological depletion of serotonin and norepinephrine with para-chlorophenylalanine and alpha-methyl-p-tyrosine reverses the antidepressant-like effects of adolescent caffeine exposure in the male rat.,Behav Pharmacol. 2020 Sep 3. doi: 10.1097/FBP.0000000000000588. Online ahead of print.,"Caffeine-treated adolescent male rats were exposed to caffeine (0.25 g/L) in their drinking water beginning on P28. A-methyl-p-tyrosine, para-chlorophenylalanine, or saline were administered prior to light-dark, open field, and forced swim testing beginning on P45. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"p28 Bacterial Peptide, as an Anticancer Agent.",Front Oncol. 2020 Aug 6;10:1303. doi: 10.3389/fonc.2020.01303. eCollection 2020.,"The peptide, p28, is a post-translational, multi-target anticancer agent that preferentially enters a wide variety of solid tumor cells. ...Here, we review the current basic and clinical evidence suggesting the potential of p28 as a cancer therapeutic peptide...."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Interleukin-27 Functional Duality Balances Leishmania Infectivity and Pathogenesis.,Front Immunol. 2020 Aug 7;11:1573. doi: 10.3389/fimmu.2020.01573. eCollection 2020.,
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Electrowetting-on-dielectric characteristics of ZnO nanorods.,Sci Rep. 2020 Aug 25;10(1):14194. doi: 10.1038/s41598-020-71017-7.,
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.,Am J Trop Med Hyg. 2020 Aug 17. doi: 10.4269/ajtmh.20-0531. Online ahead of print.,"In C57BL/6 wild-type mice with established liver infection, a single injection of anti-IL-27 p28 or anti-IL-10R monoclonal antibody enhanced granuloma assembly, enabled macrophage activation, and induced comparable parasite killing (49-56%). However, anti-IL-27 p28 …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Distinct Phases of Postnatal Skeletal Muscle Growth Govern the Progressive Establishment of Muscle Stem Cell Quiescence.,Stem Cell Reports. 2020 Sep 8;15(3):597-611. doi: 10.1016/j.stemcr.2020.07.011. Epub 2020 Aug 6.,"We identified two distinct peaks of myogenic differentiation between P7-P10 and P21-P28, and showed that the quiescent MuSC pool is established between 7 and 8 weeks of age. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,IL-27 Rα+ cells promoted allorejection via enhancing STAT1/3/5 phosphorylation.,J Cell Mol Med. 2020 Aug 6. doi: 10.1111/jcmm.15700. Online ahead of print.,"IL-27Rα(+) spleen cells accelerated allograft rejection in vivo. rIL-27 significantly promoted proliferation, inhibited apoptosis and increased STAT1/3/5 phosphorylation of alloreactive splenocytes, and these effects of rIL-27 could be almost totally blocked by JAK/ STAT inhibito …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Multiple Ehrlichia chaffeensis Genes Critical for Its Persistent Infection in a Vertebrate Host Are Identified by Random Mutagenesis Coupled with In Vivo Infection Assessment.,Infect Immun. 2020 Sep 18;88(10):e00316-20. doi: 10.1128/IAI.00316-20. Print 2020 Sep 18.,"., two 28-kDa outer membrane proteins (P28/OMP) and a 120-kDa surface protein, were also recognized as necessary for the pathogen's obligate intracellular life cycle. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"Calcium repletion to rats with calcipenic rickets fails to recover bone quality: A calcipenic ""memory"".",Bone. 2020 Jul 28;141:115562. doi: 10.1016/j.bone.2020.115562. Online ahead of print.,Female SD rats (postnatal 28 days/P28) were rendered calcipenic by feeding calcium deficient (CaD) diet (0.1% Ca) till P70 while control SD rats were fed Ca sufficient diet (0.8% Ca). ...
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Identifying the key regulators that promote cell-cycle activity in the hearts of early neonatal pigs after myocardial injury.,PLoS One. 2020 Jul 30;15(7):e0232963. doi: 10.1371/journal.pone.0232963. eCollection 2020.,"We identified five pathways (mitogen associated protein kinase [MAPK], Hippo, cyclic [cAMP], Janus kinase/signal transducers and activators of transcription [JAK-STAT], and Ras) which were comprehensively upregulated in cardiac tissues collected on day 7 (P7) and/or P28 of …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Fibroblast growth factor 10 is a negative regulator of postnatal neurogenesis in the mouse hypothalamus.,Development. 2020 Jul 13;147(13):dev180950. doi: 10.1242/dev.180950.,"Quantitative lineage-tracing in vivo revealed that conditional deletion of fibroblast growth factor 10 (Fgf10) from Fgf10-expressing β-tanycytes at postnatal days (P)4-5 results in the generation of significantly more parenchymal cells by P28, composed mostly of ventromedi …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,"Inexpensive NaX (X = I, Br, Cl) as a halogen donor in the practical Ag/Cu-mediated decarboxylative halogenation of aryl carboxylic acids under aerobic conditions.",Org Biomol Chem. 2018 Aug 1;16(30):5416-5421. doi: 10.1039/c8ob01095a.,A gram-scale reaction and a three-step procedure to synthesize iniparib have been performed to evaluate the practicality of this protocol. ...
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.,J Biomol Struct Dyn. 2020 Jul 3:1-16. doi: 10.1080/07391102.2020.1787864. Online ahead of print.,"The second azurin derived peptide p28, fared the best among the docked proteins. p28 interacted with all the three viral proteins and the host ACE-2 receptor by forming several electrostatic and hydrogen bonds with the S-protein, 3CL(pro), and PL(pro). MD simulation …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Developmental onset distinguishes three types of spontaneous recognition memory in mice.,Sci Rep. 2020 Jun 30;10(1):10612. doi: 10.1038/s41598-020-67619-w.,"Temporal order recognition was the last to emerge, at P28. Elucidating the developmental expression of recognition memory in mice is critical to improving our understanding of the ontogeny of episodic memory, and establishes a necessary blueprint to apply these tasks to pr …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"Depletion of microglia in developing cortical circuits reveals its critical role in glutamatergic synapse development, functional connectivity, and critical period plasticity.",J Neurosci Res. 2020 Oct;98(10):1968-1986. doi: 10.1002/jnr.24641. Epub 2020 Jun 28.,"We administered PLX3397, a colony-stimulating factor 1 receptor inhibitor, to mice starting at postnatal day 14 and through P28, which depletes >75% of microglia in the visual cortex (VC). ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"In silico design of two novel fusion proteins, p28-IL-24 and p28-M4, targeted to breast cancer cells.",Res Pharm Sci. 2020 May 11;15(2):200-208. doi: 10.4103/1735-5362.283820. eCollection 2020 Apr.,"BACKGROUND AND PURPOSE: An anticancer peptide P28, has shown to be cytolethal on various cancer cells including breast cancer. ...In the present study, the impact of different linkers on construction of the two chimeric proteins (p28-IL-24 and p28-M4) was ass …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Bobby sox homolog regulates tooth root formation through modulation of dentin sialophosphoprotein.,J Cell Physiol. 2020 Jun 14. doi: 10.1002/jcp.29875. Online ahead of print.,"Until P28, the crown morphology in Bbx(-/-) mice was not distinctively different from Bbx(+/+) littermates. Meanwhile, the length of the mandibular base in Bbx(-/-) mice was notably less at P28. ...The second molar of Bbx(-/-) mice also showed 10.16% and 6.4% reduct …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Sex differences in dendritic spine density and morphology in auditory and visual cortices in adolescence and adulthood.,Sci Rep. 2020 Jun 10;10(1):9442. doi: 10.1038/s41598-020-65942-w.,"We analyzed dendritic spines in 4-week-old (P28) and 12-week-old (P84) male and female mice and found that DSD is lower in female mice due in part to fewer short stubby, long stubby and short mushroom spines. We found striking layer-specific patterns including a significan …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Serial Passaging of the Human Rotavirus CDC-9 Strain in Cell Culture Leads to Attenuation: Characterization from In Vitro and In Vivo Studies.,J Virol. 2020 Jul 16;94(15):e00889-20. doi: 10.1128/JVI.00889-20. Print 2020 Jul 16.,"Upon adaptation and passages in Vero cells, the strain underwent five amino acid changes at P28 and one additional change at P44/P45 in the VP4 gene. We performed virologic, immunological, and pathogenic characterization of wild-type CDC-9 virus at P11/P12 and its two muta …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Dynamics of the Transcriptome and Accessible Chromatin Landscapes During Early Goose Ovarian Development.,Front Cell Dev Biol. 2020 Apr 3;8:196. doi: 10.3389/fcell.2020.00196. eCollection 2020.,"Results from hematoxylin-eosin, periodic acid-Schiff, and anti-CVH immunohistochemical stainings demonstrated that programmed oocyte loss, oocyte nest breakdown and primordial follicle formation, and the primordial-to-secondary follicle transition occur during the periods from em …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,mTOR Suppresses Macroautophagy During Striatal Postnatal Development and Is Hyperactive in Mouse Models of Autism Spectrum Disorders.,Front Cell Neurosci. 2020 Mar 31;14:70. doi: 10.3389/fncel.2020.00070. eCollection 2020.,"We demonstrate that autophagic flux is suppressed during striatal postnatal development, reaching adult levels around postnatal day 28 (P28). ...Finally, we discover that autophagy is downregulated during late striatal postnatal development (P28) in mice with in ute …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,"RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.",BMC Cancer. 2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.,"METHODS: The RACE trial is a an investigator initiated multicenter, prospective, randomized, stratified phase III clinical trial and seeks to investigate the role of preoperative induction chemotherapy (2 cycles of FLOT: 5-FU, leucovorin, oxaliplatin, docetaxel) with subse …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.,JCO Precis Oncol. 2020 Feb 26;4:PO.19.00237. doi: 10.1200/PO.19.00237. eCollection 2020.,"PATIENTS AND METHODS: Patients with stage III colon cancers were randomly assigned to FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab in 2 large adjuvant phase III trials (N = 5,577). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).,Clin Colorectal Cancer. 2020 Jun 12:S1533-0028(20)30088-8. doi: 10.1016/j.clcc.2020.06.003. Online ahead of print.,"BACKGROUND: FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.,J Gastrointest Cancer. 2020 Sep 12. doi: 10.1007/s12029-020-00516-7. Online ahead of print.,"This study aimed to evaluate the feasibility and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line therapy in patients with relapsed or recurrent GI-NEC after first-line platinum plus etoposide therapy. ..."
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.,Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.,
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.,JCO Precis Oncol. 2019 Aug 23;3:PO.19.00001. doi: 10.1200/PO.19.00001. eCollection 2019.,"We prospectively evaluated fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX)-based treatment and imaging-based biomarkers for borderline resectable PDAC. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).,Invest New Drugs. 2020 Sep 10. doi: 10.1007/s10637-020-01000-6. Online ahead of print.,"Heavily pretreated patients were treated with pegilodecakin (self-administered subcutaneously daily at 2.5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Case report on 5-fluorouracil induced cerebrovascular accident.,J Oncol Pharm Pract. 2020 Sep 9:1078155220954900. doi: 10.1177/1078155220954900. Online ahead of print.,A 37 years old female patient diagnosed with carcinoma rectum underwent six cycles of chemotherapy with 5- fluorouracil- calcium leucovorin- irinotecan (FOLFIRI regimen). ...
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.,Medicine (Baltimore). 2020 Sep 4;99(36):e22060. doi: 10.1097/MD.0000000000022060.,
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.,Cancer Gene Ther. 2020 Sep 8. doi: 10.1038/s41417-020-00219-y. Online ahead of print.,"CD-NSCs were given every 2 weeks using an indwelling brain catheter, followed each time by a 7-d course of oral 5-FC (and leucovorin in the final patient cohort). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder.,Semin Pediatr Neurol. 2020 Oct;35:100835. doi: 10.1016/j.spen.2020.100835. Epub 2020 Jun 25.,"This article reviews one of these treatments, d,l-leucovorin calcium (also known as folinic acid) for treatment of folate pathway abnormalities in children with ASD. ...This article reviews the current evidence for treating core and associated symptoms and underlying patho …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,A case of chemotherapy-induced coronary vasospasm in a patient with colorectal cancer.,J Cardiol Cases. 2020 Jun 10;22(3):117-120. doi: 10.1016/j.jccase.2020.05.014. eCollection 2020 Sep.,"Here we present a case of a patient with colorectal cancer without any modifiable cardiovascular risk factors who experienced coronary vasospasm shortly after initiation of therapy with 5-flourouracil, leucovorin, and oxaliplatin with bevacizumab, despite having previously …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan.,Ther Adv Med Oncol. 2020 Aug 17;12:1758835920944052. doi: 10.1177/1758835920944052. eCollection 2020.,"This literature review compared the clinical characteristics and outcomes of available real-world evidence (RWE) for liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV), a treatment regimen indicated for patients with metastatic pancreatic du …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.,BMC Cancer. 2020 Sep 1;20(1):832. doi: 10.1186/s12885-020-07347-6.,"Patients received dose-dense TPF (ddTPF) with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept.,In Vivo. 2020 Sep-Oct;34(5):2667-2673. doi: 10.21873/invivo.12086.,"BACKGROUND/AIM: The efficacy of aflibercept plus 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) therapy has been demonstrated in patients with metastatic colorectal cancer (mCRC) in global and Japanese clinical trials. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).,BMC Cancer. 2020 Aug 31;20(1):822. doi: 10.1186/s12885-020-07268-4.,"BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular al …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,5-Fluorouracil Rechallenge After Cardiotoxicity.,Am J Case Rep. 2020 Aug 29;21:e924446. doi: 10.12659/AJCR.924446.,"After comprehensive risk-benefit discussions, the decision was made for palliative chemotherapy using 5-FU/leucovorin. A pre-treatment regimen including isosorbide dinitrate, diltiazem, and metoprolol was used. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.,Gut Liver. 2020 Aug 26. doi: 10.5009/gnl20070. Online ahead of print.,"The current study compared clinical outcomes between gemcitabine and FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) in patients with BRPC. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Systemic treatment of advanced or recurrent biliary tract cancer.,Biosci Trends. 2020 Aug 24. doi: 10.5582/bst.2020.03240. Online ahead of print.,"Chemotherapy, and especially a triplet regimen based on gemcitabine/cisplatin/nab-paclitaxel, has had the most significant effect, and fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) combined with bevacizumab is promising. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,"Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials.",J Clin Med. 2020 Aug 16;9(8):2654. doi: 10.3390/jcm9082654.,"BACKGROUND: The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.,J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print.,"PURPOSE: A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have investigated this reg …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,"Letter to Editor Regarding ""Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma"".",Biol Blood Marrow Transplant. 2020 Sep 17:S1083-8791(20)30597-8. doi: 10.1016/j.bbmt.2020.08.032. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,"Response to Letter to Editor Regarding ""Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma"".",Biol Blood Marrow Transplant. 2020 Sep 17:S1083-8791(20)30598-X. doi: 10.1016/j.bbmt.2020.09.009. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.,Oncoimmunology. 2020 Jun 10;9(1):1777064. doi: 10.1080/2162402X.2020.1777064.,"Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the European Medicines Agency. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Advances in chimeric antigen receptor T cells.,Curr Opin Hematol. 2020 Sep 10. doi: 10.1097/MOH.0000000000000614. Online ahead of print.,"In the United States, the Food and Drug Administration (FDA) approved Tisagenlecleucel for the treatment of relapsed/refractory B-ALL and Axicabtagene Ciloleucel, for adults with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) in 2017. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,[Advances in antibody therapy for B cell lymphoma].,Rinsho Ketsueki. 2020;61(8):901-911. doi: 10.11406/rinketsu.61.901.,"In this review, molecular mechanisms of the second/third generation anti-CD20 antibodies (ofatumumab and obinutuzumab), anti-CD19 chimeric antigen-receptor T-cells (CAR-T-CD19; tisagenlecleucel, axicabtagene ciloleucel), and the anti-PD-1 antibodies (nivolumab and p …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,[The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].,Bull Cancer. 2020 Sep 2:S0007-4551(20)30315-5. doi: 10.1016/j.bulcan.2020.05.014. Online ahead of print.,"In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.,Expert Opin Biol Ther. 2020 Sep 21:1-16. doi: 10.1080/14712598.2020.1819978. Online ahead of print.,Cancer immunotherapy witnessed a major breakthrough with the US FDA approval of the first chimeric antigen receptor (CAR) T-cell therapy Kymriah(TM) (tisagenlecleucel) for relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) in August 2017 followed by approval of Yesca …
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.,Blood Adv. 2020 Aug 25;4(16):3943-3951. doi: 10.1182/bloodadvances.2020002228.,We conducted a cohort analysis of 100 consecutive patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel). ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials.,Curr Res Transl Med. 2020 Aug 15:S2452-3186(20)30038-6. doi: 10.1016/j.retram.2020.05.005. Online ahead of print.,"Two CAR T products, namely axicabtagene ciloleucel and tisagenlecleucel, are commercially available and represent genetically engineered T cells expressing chimeric receptors for CD19. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Neurological adverse events following CAR T-cell therapy: a real-world analysis.,Immunotherapy. 2020 Aug 18. doi: 10.2217/imt-2020-0161. Online ahead of print.,Materials & methods: Postmarketing case reports from the US FDA AEs reporting system involving axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for large B-cell lymphomas were analyzed. ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years.,J Geriatr Oncol. 2020 Aug 11:S1879-4068(20)30145-4. doi: 10.1016/j.jgo.2020.07.006. Online ahead of print.,INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug Administration (FDA) approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel …
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.,Bone Marrow Transplant. 2020 Aug 11. doi: 10.1038/s41409-020-01029-4. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.,Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.,"We included patients who received axicabtagene ciloleucel (n = 30) or tisagenlecleucel (n = 10) for B-cell lymphoma, CD19-28z CAR T therapy for B-cell acute lymphoblastic leukemia (NCT01044069; n = 37), or B-cell maturation antigen targeting CAR T cells for multiple …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.,JAMA Neurol. 2020 Aug 10:e202703. doi: 10.1001/jamaneurol.2020.2703. Online ahead of print.,A consecutive sample of all patients undergoing CAR T-cell therapy with axicabtagene ciloleucel for relapsed or refractory lymphoma were assessed for inclusion (n = 213). ...
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.,Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors.,J Chin Med Assoc. 2020 Aug;83(8):719-724. doi: 10.1097/JCMA.0000000000000358.,"In 2017 and 2018, Food and Drug Administration has approved YESCARTA (axicabtagene ciloleucel) and KYMRIAH (tisagenlecleucel), two chimeric antigen receptor (CAR)-engineered T-cell products, for B-cell malignancies. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.,J Allergy Clin Immunol. 2020 Aug 6:S0091-6749(20)31099-X. doi: 10.1016/j.jaci.2020.07.025. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes.,Neuro Oncol. 2020 Aug 5:noaa183. doi: 10.1093/neuonc/noaa183. Online ahead of print.,"METHODS: Patients (n=45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.,Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25951. Online ahead of print.,Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,CD19-directed CAR T-cell therapy in B-cell NHL.,Curr Opin Oncol. 2020 Sep;32(5):408-417. doi: 10.1097/CCO.0000000000000668.,This has led to Food and Drug Administration and European Medicines Agency approval for axicabtagene ciloleucel and tisagenlecleucel and filing of the biologics license application for lisocabtagene maraleucel. ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.,Haematologica. 2020 Jul 30:haematol.2020.254045. doi: 10.3324/haematol.2020.254045. Online ahead of print.,"To characterize these late events, we analyzed 31 patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel at our institution on 2 clinical trials, ZUMA-1 (NCT02348216) and ZUMA-9 (NCT03153462). ...These results suggest the nee …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.,BMC Bioinformatics. 2020 Jul 25;21(1):333. doi: 10.1186/s12859-020-03655-7.,"RESULTS: Focusing on two ""use cases"" of two-arm clinical trials, one for metastatic colorectal cancer (CRC) patients treated with the anti-angiogenic molecule aflibercept, and the other for triple negative breast cancer (TNBC) patients treated with the small molecule iniparib …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.,Expert Opin Pharmacother. 2020 Apr;21(6):679-686. doi: 10.1080/14656566.2020.1724283. Epub 2020 Feb 19.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.,BMC Vet Res. 2020 Jan 31;16(1):30. doi: 10.1186/s12917-020-2247-4.,Early investigations show tolerability of iniparib in dogs. PARP inhibitors also imply higher therapy costs and consequently are less likely to be accepted by pet owners.We summarized the current evidence of canine BRCA2 gene alterations and their association with mammary …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.,J Immunother Cancer. 2019 Oct 23;7(1):274. doi: 10.1186/s40425-019-0740-8.,"She developed mTNBC in 2009 and was sequentially treated with capecitabine, gemcitabine-carboplatin-iniparib (GCI), XRT and an experimental vaccine. ..."
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.,Breast Cancer Res Treat. 2019 Sep;177(2):383-393. doi: 10.1007/s10549-019-05305-w. Epub 2019 Jun 6.,"Pharmacokinetics of iniparib and its two metabolites were analyzed. RESULTS: A total of 163 patients were randomized, 82 GC+w-iniparib and 81 GC+tw-iniparib. ...Iniparib plasma concentrations and exposure were two-fold higher with w-iniparib com …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.,Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.,"Other targeted agents like iniparib, sorafenib, cetuximab, and ipatasertib combined with CT showed significant superiority in PFS compared with CT alone, and the HRs were 0.75 (0.62-0.90), 0.44 (0.21-0.91), 0.67 (0.47-0.96), and 0.44 (0.24-0.81), respectively, while some o …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Iniparib for newly diagnosed glioblastoma.,Lancet Oncol. 2018 Oct;19(10):e514. doi: 10.1016/S1470-2045(18)30665-X. Epub 2018 Aug 31.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.,Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.,PURPOSE: Iniparib is a purported prodrug causing cell death through intracellular conversion to nitro radical ions. We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM). ...A …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.,Radiat Res. 2018 Nov;190(5):464-472. doi: 10.1667/RR15035.1. Epub 2018 Aug 1.,"For clonogenic assays, STS cell lines were irradiated with or without olaparib, iniparib or veliparib pretreatment. The effect of PARP inhibition on γ-H2AX and Rad51 foci formation, on PARP-1, phospho-ERK and cleaved caspase-3 protein expression and on cell cycle progressi …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.,J Exp Clin Cancer Res. 2009 Feb 14;28(1):18. doi: 10.1186/1756-9966-28-18.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.,Medicine (Baltimore). 2017 Nov;96(45):e8389. doi: 10.1097/MD.0000000000008389.,"In the regression analysis, Bevacizumab (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.43-2.05; P Iniparib (OR, 1.51; 95% CI, 1.11-2.07; P = .009) corre …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.,PLoS One. 2017 Aug 17;12(8):e0183578. doi: 10.1371/journal.pone.0183578. eCollection 2017.,"Myc/MDA-468 cells were resistant to standard chemotherapeutic treatments such as iniparib (PARP inhibitor) plus cisplatin, / iniparib, cisplatin, paclitaxel and docetaxel. However, Myc/MDA-231 cells, which showed EMT changes responded to iniparib with cisplat …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro.,Mol Med Rep. 2017 Jul;16(1):208-214. doi: 10.3892/mmr.2017.6568. Epub 2017 May 10.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.,Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.,"We evaluated this mechanism of resistance in newly diagnosed patients with BRCA1/2-mutant breast cancer with poor response to neoadjuvant platinum-based therapy.Experimental Design: PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin, and iniparib in p …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.,Radiology. 2017 Feb;282(2):453-463. doi: 10.1148/radiol.2016161929. Epub 2016 Nov 14.,"The area under the receiver operating characteristic curve (AUC, in g/mL· min) for (18)F-FTT was assessed in normal mouse organs before and after treatment with olaparib (n = 14), a PARP inhibitor, or iniparib (n = 11), which has no PARP inhibitory activity. ...Results In …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.,Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.,"RESULTS: In a trial of neoadjuvant platinum, gemcitabine, and iniparib, HR deficiency predicted residual cancer burden score of 0 or I (RCB 0/I) and pathologic complete response (pCR; OR = 4.96, P = 0.0036; OR = 6.52, P = 0.0058). ...When restricted to BRCA1/2 nonmutated t …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.,PLoS One. 2016 Feb 11;11(2):e0149194. doi: 10.1371/journal.pone.0149194. eCollection 2016.,Dogs were treated with iniparib alone and in combination with carboplatin chemotherapy. Iniparib doses ranged between 10-70 mg/kg intravenously (IV). ...The maximum tolerated dose (MTD) of iniparib was not identified. Moderate to high variability in plasma ex …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.,J Breast Cancer. 2015 Dec;18(4):329-38. doi: 10.4048/jbc.2015.18.4.329. Epub 2015 Dec 23.,"METHODS: We have evaluated the in vitro synergistic effect of combinations of trabectedin and three different PARP inhibitors (veliparib, olaparib, and iniparib) in four breast cancer cell lines, each presenting a different BRCA1 genetic background. ...Synergistic effects …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Tumor Microenvironment Targeting Nano-Bio Emulsion for Synergistic Combinational X-Ray PDT with Oncolytic Bacteria Therapy.,Adv Healthc Mater. 2020 Jul;9(13):e1901812. doi: 10.1002/adhm.201901812. Epub 2020 Jun 11.,"Herein, a nano-bio therapeutic emulsion formulated with multifunctional nanoscintillators and anaerobic Clostridium novyi-NT spores for synergistic image-guided combinational cancer therapy is reported. ...An anaerobic oncolytic bacterium (C. novyi- …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Iron-Oxide Nanocluster Labeling of Clostridium novyi-NT Spores for MR Imaging-Monitored Locoregional Delivery to Liver Tumors in Rat and Rabbit Models.,J Vasc Interv Radiol. 2019 Jul;30(7):1106-1115.e1. doi: 10.1016/j.jvir.2018.11.002. Epub 2019 Apr 2.,PURPOSE: To label Clostridium novyi-NT spores (C. novyi-NT) with iron oxide nanoclusters and track distribution of bacteria during magnetic resonance (MR) imaging-monitored locoregional delivery to liver tumors using intratumoral injection or in …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Immune response to C. novyi-NT immunotherapy.,Vet Res. 2018 Apr 24;49(1):38. doi: 10.1186/s13567-018-0531-0.,Clostridium novyi-NT (CVN-NT) spores germinate in hypoxic regions of tumors and have successfully cured induced neoplasia in mouse models and resulted in objective tumor responses in naturally developing neoplasia in the dog. ...Intratumoral injection …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.,BMC Vet Res. 2018 Apr 2;14(1):119. doi: 10.1186/s12917-018-1424-1.,"BACKGROUND: Clostridium novyi-NT (CNV-NT), has shown promise as a bacterolytic therapy for solid tumors in mouse models and in dogs with naturally developing neoplasia. ...RESULTS: Dogs that developed an inflammatory response to CNV-NT had a hig …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Learning from Clostridium novyi-NT: How to defeat cancer.,J Cancer Res Ther. 2018;14(Supplement):S1-S6. doi: 10.4103/0973-1482.204841.,"Here, we take ""Clostridium novyi"" for the search keyword in the PubMed from 2000 to 2015 and describe that C. novyi-NT spores act as ""Trojan horse"" for bacteriolytic therapy. ...Therefore, C. novyi-NT spores should be an effective and saf …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Branched Gold Nanoparticle Coating of Clostridium novyi-NT Spores for CT-Guided Intratumoral Injection.,Small. 2017 Feb;13(5):10.1002/smll.201602722. doi: 10.1002/smll.201602722. Epub 2016 Nov 15.,Branched gold nanoparticle (BGNP)-coated Clostridium novyi-NT (C. novyi-NT) spores are developed for computed tomography (CT)-guided bacteriolytic tumor therapy. ...
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium novyi-NT in cancer therapy.,Genes Dis. 2016 Feb 6;3(2):144-152. doi: 10.1016/j.gendis.2016.01.003. eCollection 2016 Jun.,The attenuated anaerobic bacterium Clostridium novyi-NT (C. novyi-NT) is known for its ability to precisely germinate in and eradicate treatment-resistant hypoxic tumors in various experimental animal models and spontaneously occurring canine sa …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium to treat cancer: dream or reality?,Ann Transl Med. 2015 May;3(Suppl 1):S21. doi: 10.3978/j.issn.2305-5839.2015.03.39.,"In their paper ""Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses"", Roberts et al. describe the induction of antitumor responses following local spore administration of an attenuated C. novyi strain (C. novyi-N …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.,Oncotarget. 2015 Mar 20;6(8):5536-46. doi: 10.18632/oncotarget.3627.,"The spore-forming anaerobic bacterium Clostridium novyi-NT(C. novyi-NT) has the ability to propagate in tumor-generated hypoxia, leading to oncolysis. Here, we show that intravenously injected spores of C. novyi-NT led to dramatic …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,MRI-monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model.,PLoS One. 2014 Dec 30;9(12):e116204. doi: 10.1371/journal.pone.0116204. eCollection 2014.,OBJECTIVES: To validate the feasibility of labeling Clostridium novyi-NT (C.novyi-NT) anaerobes with iron-oxide nanoparticles for magnetic resonance imaging (MRI) and demonstrate the potential to use MRI to visualize intra-tumoral delivery of th …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.,Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982.,"Species of Clostridium bacteria are notable for their ability to lyse tumor cells growing in hypoxic environments. We show that an attenuated strain of Clostridium novyi (C. novyi-NT) induces a microscopically precise, tumor-localized response i …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.,Magn Reson Med. 2013 Dec;70(6):1690-8. doi: 10.1002/mrm.24955. Epub 2013 Oct 7.,"METHODS: The CEST parameters of the anaerobic gram-positive bacterium Clostridium novyi-NT (C. novyi-NT) were first characterized in vitro, then used to detect C. novyi-NT germination and infection in subcutaneous CT26 colorectal t …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors.,Am J Vet Res. 2012 Jan;73(1):112-8. doi: 10.2460/ajvr.73.1.112.,OBJECTIVE: To establish the maximum tolerated dose of Clostridium novyi-NT spores in tumor-bearing dogs and evaluate spore germination within tumors and tumor response. ...Clostridium novyi-NT was cultured from 1 of 6 tumors. Five dogs we …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Structural characterization of the polar lipids of Clostridium novyi NT. Further evidence for a novel anaerobic biosynthetic pathway to plasmalogens.,Biochim Biophys Acta. 2011 Mar;1811(3):186-93. doi: 10.1016/j.bbalip.2010.12.010. Epub 2010 Dec 30.,"A study of the polar lipids of Clostridium novyi NT has revealed the presence of phosphatidylethanolamine (PE) and cardiolipin as major phospholipids with smaller amounts of phosphatidylglycerol (PG), lysyl-PG and alanyl-PG. ...These findings are consistent w …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Bacteriolytic therapy of experimental pancreatic carcinoma.,World J Gastroenterol. 2010 Jul 28;16(28):3546-52. doi: 10.3748/wjg.v16.i28.3546.,"AIM: To investigate the effectiveness of Clostridium novyi (C. novyi)-NT spores for the treatment of established subcutaneous pancreatic tumor in the syngeneic, immunocompetent Panc02/C57Bl/6 model. METHODS: C. novyi-NT spores were applie …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Combination of a fluorescent dye and a Zn-S cluster and its biological application as a stain for bacteria.,Inorg Chem. 2010 Feb 15;49(4):1319-21. doi: 10.1021/ic9023629.,"An ionic-pair charge-transfer salt [C(15)H(16)N(3)](+)[Zn(8)S(SC(6)H(5))(15).H(2)O](-) (1) featuring a fluorescent dye and a wurtzite-like octanuclear Zn-S cluster shows high stability when staining bacteria Escherichia coli, Salmonella typhimurium, and Clostridium novy …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,"Targeting cancer with bugs and liposomes: ready, aim, fire.",Cancer Res. 2007 Oct 15;67(20):9605-8. doi: 10.1158/0008-5472.CAN-07-1565.,This article will highlight the recent advance in using a novel lipase secreted by the tumor-colonizing anaerobic bacterium Clostridium novyi-NT to induce the targeted release of liposomal payloads within tumors....
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Spore coat architecture of Clostridium novyi NT spores.,J Bacteriol. 2007 Sep;189(17):6457-68. doi: 10.1128/JB.00757-07. Epub 2007 Jun 22.,"Spores of the anaerobic bacterium Clostridium novyi NT are able to germinate in and destroy hypoxic regions of tumors in experimental animals. ...In addition to their implications for understanding the biology of C. novyi NT, these studies docum …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,A bacterial protein enhances the release and efficacy of liposomal cancer drugs.,Science. 2006 Nov 24;314(5803):1308-11. doi: 10.1126/science.1130651.,"Clostridium novyi-NT is an anaerobic bacterium that can infect hypoxic regions within experimental tumors. Because C. novyi-NT lyses red blood cells, we hypothesized that its membrane-disrupting properties could be exploited to enhance the relea …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT.,Nat Biotechnol. 2006 Dec;24(12):1573-80. doi: 10.1038/nbt1256. Epub 2006 Nov 19.,"Clostridium novyi-NT spores represent one of the most promising of these agents, as they generate potent anti-tumor effects in experimental animals. We have determined the 2.55-Mb genomic sequence of C. novyi-NT, identifying a new type of transp …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.,Sci Rep. 2019 Jun 24;9(1):9130. doi: 10.1038/s41598-019-45589-y.,"Combination treatment with KTN3379, a monoclonal antibody targeted against HER3, and BYL719 led to enhanced suppression of in vitro and in vivo cancer growth and durable suppression of AKT and S6. Therefore, inhibition of HER3 with KTN3379 enhanced the effects of PI …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.,PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017.,"Surprisingly, we found that while NRG1 is required for ErbB3 activation, it was not sufficient to fully predict for KTN3379 activity. ...Furthermore, NRG1-positive HNSCC cell lines that secreted high levels of AREG and TGFα or contained high levels of EGFR homodimers (H11D …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.,Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.,"The dependency of HPV(+) and HPV(-) HNSCC models on HER3 was evaluated with anti-HER3 siRNAs and the clinical stage anti-HER3 monoclonal antibody KTN3379.Results: HER3 was overexpressed in HPV(+) HNSCC, where it was associated with worse overall survival in patients with p …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.,BMJ Case Rep. 2016 Sep 2;2016:bcr2016216273. doi: 10.1136/bcr-2016-216273.,A patient with grade VI KRAS mutation rectal cancer with metastasis to the lung and cerebellum presented with left eye choroidal metastasis 1 week after being started on the experimental medication KTN3379. ...
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.,Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15.,We developed a fully human mAb against HER3 (KTN3379) that efficiently suppressed HER3 activity in both ligand-dependent and independent settings. ...KTN3379 is currently undergoing a phase Ib clinical trial in patients with advanced solid tumors. Our current study …
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.,Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13225-30. doi: 10.1073/pnas.1518361112. Epub 2015 Oct 12.,"Here we describe the crystal structure of the Fab fragment of an antagonistic monoclonal antibody KTN3379, currently in clinical development in human cancer patients, in complex with the ErbB3 extracellular domain. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.,Exp Hematol Oncol. 2017 Nov 28;6:31. doi: 10.1186/s40164-017-0091-4. eCollection 2017.,"MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. ...Ertumaxomab enhanced the interaction of immune effector cells and tumor c …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.,BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.,"BACKGROUND: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Targeting the HER2 receptor in metastatic breast cancer.,Hematol Oncol Stem Cell Ther. 2012;5(3):127-37. doi: 10.5144/1658-3876.2012.127.,"Several other targeted agents, including T-DM1, pertuzumab, neratinib, afatinib and ertumaxomab, are currently being tested in vivo as well as in clinical studies. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.,MAbs. 2012 Sep-Oct;4(5):614-22. doi: 10.4161/mabs.21003. Epub 2012 Jul 23.,"Whether molecular effects, however, might contribute to the cellular antitumor efficiency of ertumaxomab are largely unknown. ...RESULTS: The Kd of ertumaxomab for Her2-binding was determined at 265 nM and the ertumaxomab binding epitope was found to not over …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.,Clin Transl Oncol. 2011 Dec;13(12):889-98. doi: 10.1007/s12094-011-0751-5.,"BACKGROUND Trifunctional antibodies, such as catumaxomab (anti-EpCAM×anti-CD3) and ertumaxomab (anti- HER-2/neu×anti-CD3), transiently link immune effector cells to tumour cells, which results in cellular cytotoxicity towards the tumour cells. ...The potency of catumaxomab …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Targeted therapy in breast cancer: what's new?,Swiss Med Wkly. 2011 Jun 27;141:w13231. doi: 10.4414/smw.2011.13231. eCollection 2011.,"In this review we discuss the major newly developed targeted agents in breast cancer treatment, including the novel anti-HER-2 monoclonal antibody pertuzumab or ertumaxomab, small molecular tyrosine inhibitor lapatinib, selective PARP1 inhibitor olaparib, mTOR inhibitor ra …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Structural and functional characterization of the trifunctional antibody catumaxomab.,MAbs. 2010 May-Jun;2(3):309-19. doi: 10.4161/mabs.2.3.11791. Epub 2010 May 16.,"., EpCAM (catumaxomab), HER2/neu (ertumaxomab), CD20 (FBTA05), gangliosides GD2/GD3 (Ektomun), on appropriate tumor target cells associated with carcinomas, lymphomas or melanomas. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Evolving novel anti-HER2 strategies.,Lancet Oncol. 2009 Dec;10(12):1179-87. doi: 10.1016/S1470-2045(09)70315-8.,
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.,Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12.,"The trifunctional antibody ertumaxomab targets HER2/neu, CD3, and activating Fcgamma receptors. In presence of ertumaxomab, tri-cell complexes consisting of tumor cells, T cells, and accessory cells form to cause tumor cell lysis. ...Ertumaxomab-mediated acti …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.,Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3.,"A series of novel HER-2-targeting agents is also presented, including pertuzumab, ertumaxomab, HER-2 vaccines, and recently discovered tyrosine kinase inhibitors. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Ertumaxomab: a trifunctional antibody for breast cancer treatment.,Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. doi: 10.1517/13543784.17.10.1553.,"Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fcgamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell. ...Owing to efficient tumour cell de …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,ErbB-directed immunotherapy: antibodies in current practice and promising new agents.,Immunol Lett. 2008 Mar 15;116(2):126-40. doi: 10.1016/j.imlet.2007.12.001. Epub 2007 Dec 26.,"In this review, we discuss the biological and clinical background of ErbB targeting, and describe the most successful antibodies against ErbB1 (cetuximab, panitumumab, matuzumab, nimotuzumab, ICR62, mAb 528, ch806 and MDX-447) and ErbB2 (trastuzumab, pertuzumab, MDX-H210, 2B1, C6 …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40.,"This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, bela …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.,Clin Cancer Res. 2006 May 15;12(10):3085-91. doi: 10.1158/1078-0432.CCR-05-2436.,"EXPERIMENTAL DESIGN: Three ascending doses of ertumaxomab (10-200 microg) were administered i.v. on day 1, 7 +/- 1, and 13 +/- 1. ...DISCUSSION: Treatment with triple infusions of ertumaxomab yields a strong immunologic response. Doses up to 100 microg can be safely …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.,Pharmacol Res. 2015 Sep;99:202-16. doi: 10.1016/j.phrs.2015.06.007. Epub 2015 Jun 25.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.,PLoS One. 2014 Dec 26;9(12):e115228. doi: 10.1371/journal.pone.0115228. eCollection 2014.,"Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimycin HCl), a potent and selective inhibitor of HSP90, in combination with the microtubule targeting agent (MTA) docetaxel, in preclinical models of NSCLC. ...Our data provide a p …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Discontinued in 2013: oncology drugs.,Expert Opin Investig Drugs. 2015 Jan;24(1):95-110. doi: 10.1517/13543784.2015.971154. Epub 2014 Oct 14.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.,J Neurooncol. 2014 Dec;120(3):473-81. doi: 10.1007/s11060-014-1579-y. Epub 2014 Aug 13.,"Retaspimycin hydrochloride (IPI-504), an Hsp90 (heat shock protein 90) inhibitor, has shown activity in multiple preclinical cancer models, such as lung, breast and ovarian cancers. ...The effects of IPI-504 on cell proliferation, apoptosis, mot …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.,Clin Cancer Res. 2013 Nov 1;19(21):6020-9. doi: 10.1158/1078-0432.CCR-13-0953. Epub 2013 Sep 17.,"This phase I study investigated the safety and maximum tolerated dose (MTD) of retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS). ...Exp …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Hsp90 inhibitors in breast cancer: a systematic review.,Breast. 2013 Oct;22(5):569-78. doi: 10.1016/j.breast.2013.06.003. Epub 2013 Jul 17.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.,Breast Cancer Res Treat. 2013 May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. Epub 2013 Apr 12.,"Retaspimycin HCl at 300 mg/m² weekly in combination with trastuzumab was well tolerated and without significant toxicities. Modest clinical activity was observed, but did not meet criteria for trial expansion. The safety profile for patients on study raises the possibility …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Geldanamycin and its derivatives as Hsp90 inhibitors.,Front Biosci (Landmark Ed). 2012 Jun 1;17:2269-77. doi: 10.2741/4050.,"Therefore, its analogues, including 17AAG, 17DMAG, Tanespimycin and Retaspimycin hydrochloride, with improved pharmacokinetic profiles, have been developed...."
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.,Leuk Lymphoma. 2011 Dec;52(12):2308-15. doi: 10.3109/10428194.2011.600481. Epub 2011 Aug 18.,"Abstract A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m(2) followed by 10 days off-treatment was conducted to determine the safety and maximum tolerated do …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,"The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.",Mol Cancer Ther. 2011 Oct;10(10):1897-908. doi: 10.1158/1535-7163.MCT-11-0148. Epub 2011 Aug 8.,The observation that heat shock protein 90 (HSP90) inhibition results in KIT degradation prompted us to assess the efficacy of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) alone or in combination with imatinib or sunitinib in two GIST xenografts w …
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,"Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.",Urology. 2011 Sep;78(3):626-30. doi: 10.1016/j.urology.2011.04.041. Epub 2011 Jul 18.,OBJECTIVE: To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC). ...IPI-504 is being investigated at less-intensive doses and schedules in other tumor types …
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.,Curr Top Med Chem. 2009;9(15):1386-418. doi: 10.2174/156802609789895719.,"Infinity Pharmaceuticals is developing IPI-504 or retaspimycin hydrochloride as an intravenous product, which is in several Phase 2 clinical trials; IPI-504 is the hydroquinone hydrochloride salt of 17-AAG. More recently, Infinity Pharmaceutical …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.,Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83. doi: 10.1517/13543780903158934.,"In contrast, retaspimycin, or IPI-504, a derivative of geldanamycin and 17-AAG, is highly soluble in water and generally well tolerated. ...This article reviews IPI-504 and its utility in a wide variety of cancer phenotypes...."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.,Curr Drug Metab. 2020 Sep 18. doi: 10.2174/1389200221999200918141239. Online ahead of print.,"Currently, however, other first or second line therapeutic options have also shown efficacy against HCC, such as multikinase inhibitors (Regorafenib, Lenvatinib, and Cabozantinib), a monoclonal antibody against the vascular endothelial growth factor receptor 2 (Ramucirumab …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.,Medicine (Baltimore). 2020 Sep 18;99(38):e22312. doi: 10.1097/MD.0000000000022312.,"INTERVENTIONS: After failed transarterial chemoembolization therapy, he was initially treated with immunotherapy pembrolizumab plus angiogenesis inhibitor lenvatinib, and after 3 months of treatment, the condition improved. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.,Oncol Rep. 2020 Aug 7. doi: 10.3892/or.2020.7720. Online ahead of print.,"The increase observed in tumor volume was 26.9‑ and 12.2‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8 and 1.6‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. . …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.,Hepatol Res. 2020 Sep 13. doi: 10.1111/hepr.13567. Online ahead of print.,"RESULTS: A total of 291 and 54 patients received sorafenib and lenvatinib as first-line TKI therapy, respectively. The median OS of patients treated with TKI were significantly stratified by ALBI grade (grade 1, 20.1 months; grade 2a, 16.3 months; grades 2b and 3, 9.8 mont …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.,Pharmacol Res. 2020 Sep 8;160:105195. doi: 10.1016/j.phrs.2020.105195. Online ahead of print.,
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer.,Thyroid. 2020 Sep 10. doi: 10.1089/thy.2020.0276. Online ahead of print.,"BACKGROUND: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. ...The aims of this study were a) to evaluate, and compared to other series, the safety of lenvatinib used in RR-DTC patients …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report.,Int Cancer Conf J. 2020 Aug 18;9(4):244-248. doi: 10.1007/s13691-020-00436-0. eCollection 2020 Oct.,"Thereafter, the patient was prescribed the molecularly targeted drug, lenvatinib (12 mg/day). However, lenvatinib was not effective, as evident by the extension of several metastases. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Optimizing Survival by Changing the Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.,J Natl Cancer Inst. 2020 Sep 8:djaa119. doi: 10.1093/jnci/djaa119. Online ahead of print.,"In the first-line, atezolizumab plus bevacizumab statistically significantly improved overall survival (OS) and patient-reported outcomes (PROs) compared with sorafenib, while lenvatinib demonstrated non-inferior OS. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.,J Hepatobiliary Pancreat Sci. 2020 Sep 7. doi: 10.1002/jhbp.821. Online ahead of print.,We aimed to identify essential factors contributing to achieve sufficient treatment intensity of lenvatinib. METHODS: Seventy-one patients who received treatment with lenvatinib were included in this study. ...CONCLUSIONS: Maintaining high 2M-DBR of lenvatinib …
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.,Endocrine. 2020 Sep 3. doi: 10.1007/s12020-020-02477-0. Online ahead of print.,PURPOSE: Lenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). ...
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Targeting angiogenesis for liver cancer: Past, present, and future.",Genes Dis. 2020 Apr 7;7(3):328-335. doi: 10.1016/j.gendis.2020.03.010. eCollection 2020 Sep.,"Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.,Oncology. 2020 Sep 3:1-11. doi: 10.1159/000509387. Online ahead of print.,"BACKGROUND: Although a strong antitumor effect of lenvatinib (LEN) has been noted for patients with unresectable hepatocellular carcinoma (HCC), there are still no reports on the prognosis for patients with disease progression after first-line LEN therapy. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.,Anticancer Res. 2020 Sep;40(9):5271-5276. doi: 10.21873/anticanres.14531.,BACKGROUND/AIM: Hepatic encephalopathy is an adverse event resulting from lenvatinib use in patients with hepatocellular carcinoma (HCC). ...CONCLUSION: Lenvatinib might directly disturb hepatocyte metabolism to result in increased serum ammonia concentration....
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.,Oncology. 2020 Sep 2:1-8. doi: 10.1159/000509005. Online ahead of print.,BACKGROUND AND AIMS: Lenvatinib is an oral anticancer drug for patients with unresectable advanced hepatocellular carcinoma (HCC). ...CONCLUSION: Reduction in tumor stain at 2 weeks after lenvatinib treatment may be an early biomarker of efficacy at 12 weeks in pati …
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.",World J Gastroenterol. 2020 Aug 14;26(30):4465-4478. doi: 10.3748/wjg.v26.i30.4465.,"BACKGROUND: Lenvatinib has become an indispensable part of treatment regimens for patients with advanced hepatocellular carcinoma (aHCC). ...This necessitates further real-world studies of lenvatinib across diverse populations, such as in China. AIM: To investigate …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.,In Vivo. 2020 Sep-Oct;34(5):2859-2864. doi: 10.21873/invivo.12113.,"BACKGROUND/AIM: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. ...PATIENTS AND METHODS: We retrospectively analyzed the prognostic significance of the NLR in …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma.,Crit Rev Oncog. 2020;25(1):47-55. doi: 10.1615/CritRevOncog.2020034985.,"Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.",PLoS One. 2020 Aug 28;15(8):e0237370. doi: 10.1371/journal.pone.0237370. eCollection 2020.,"Moreover, we treated 12 HCC patients with lenvatinib and investigated the changes in MT during lenvatinib therapy. RESULTS: The serum level of Cu was positively correlated with alanine aminotransferase and the BCLC stage. ...MT levels increased in HCC patients recei …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.,PLoS One. 2020 Aug 25;15(8):e0238207. doi: 10.1371/journal.pone.0238207. eCollection 2020.,"Among 5 patients treated with tyrosine kinase inhibitors, 4 treated with lenvatinib showed stable disease or a partial response at the first treatment response. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.,Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463. doi: 10.21037/hbsn-20-480.,"The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Novel Recurrent COL5A1 Genetic Variant Is Associated With a Dysplasia-Associated Arterial Disease Exhibiting Dissections and Fibromuscular Dysplasia.,Arterioscler Thromb Vasc Biol. 2020 Sep 17:ATVBAHA119313885. doi: 10.1161/ATVBAHA.119.313885. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE-/- mice.,Atherosclerosis. 2020 Aug 27;310:64-74. doi: 10.1016/j.atherosclerosis.2020.08.003. Online ahead of print.,"Then, using a repetitive multiple site strategy, the mice were immunized with a Keyhole limpet haemocyanin (KLH) conjugated G3BP2 peptide for 2 weeks from weeks 16 to 18. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir.,Molecules. 2020 Sep 7;25(18):E4075. doi: 10.3390/molecules25184075.,These immunogens were the DRV conjugates with keyhole limpet hemocyanin (KLH) protein. The first immunogen (DRV-KLH) was prepared by zero-length direct linking of DRV via its aromatic amino group with the tyrosine amino acid residues of KLH by diazotization/c …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Identification of a protective epitope in Japanese encephalitis virus NS1 protein.,Antiviral Res. 2020 Sep 6;182:104930. doi: 10.1016/j.antiviral.2020.104930. Online ahead of print.,"Furthermore, mice immunized with KLH-polypeptide ((225)PETHTLWGD(233)) showed reduced mortality following JEV challenge. Collectively, we found a new protective epitope in the JEV NS1 protein. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al.",Ann Rheum Dis. 2020 Sep 7:annrheumdis-2020-218910. doi: 10.1136/annrheumdis-2020-218910. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Intranasal delivery of a nicotine vaccine candidate induces antibodies in mouse blood and lung mucosal secretions that specifically neutralize nicotine.,Drug Dev Ind Pharm. 2020 Sep 15:1-9. doi: 10.1080/03639045.2020.1820033. Online ahead of print.,METHODS: Nicotine-keyhole limpet hemocyanin conjugate (Nic-KLH) was prepared and mixed with monophosphoryl lipid A (MPL) as an adjuvant. ...The nicotine-specific IgG level in mice nasally immunized with Nic-KLH/MPL was lower than in mice subcutaneously immunized wit …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Bone mineral density and fracture risk in adult patients with hypophosphatasia.,Osteoporos Int. 2020 Sep 2. doi: 10.1007/s00198-020-05612-9. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Fit-for-Purpose Validation and Establishment of Assay Acceptance and Reporting Criteria of Dendritic Cell Activation Assay Contributing to the Assessment of Immunogenicity Risk.,AAPS J. 2020 Aug 24;22(5):114. doi: 10.1208/s12248-020-00491-8.,"., background control (BC)), keyhole limpet hemocyanin (KLH) as system positive control (SPC), and 2 therapeutic monoclonal antibodies (mAbs) with known clinical immunogenicity profiles (bococizumab and TAM163) as therapeutic controls (TCs). ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Methodological considerations for assessing immune defense in reproductive females.,Integr Comp Biol. 2020 Aug 20:icaa098. doi: 10.1093/icb/icaa098. Online ahead of print.,"Previous work within pharmacological research has reported that the response to the commonly-used antigen keyhole limpet hemocyanin (KLH) varies among individuals and between females and males. In this heuristic analysis, we characterize antibody responses to KLH in …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al.",Ann Rheum Dis. 2020 Aug 12:annrheumdis-2020-218713. doi: 10.1136/annrheumdis-2020-218713. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Letter by Helgestad et al Regarding Article, ""The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support"".",Circulation. 2020 Aug 11;142(6):e72-e73. doi: 10.1161/CIRCULATIONAHA.119.045133. Epub 2020 Aug 10.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,[Knee revision arthroplasty-a increasing challenge].,Oper Orthop Traumatol. 2020 Aug;32(4):271-272. doi: 10.1007/s00064-020-00670-y.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.,Neurology. 2020 Jul 29:10.1212/WNL.0000000000010380. doi: 10.1212/WNL.0000000000010380. Online ahead of print.,"All received tetanus toxoid (TT)-containing vaccine, Pneumovax® (23-PPV) and keyhole limpet hemocyanin (KLH). Group OCR was subdivided into OCR1 (n=33) and OCR2 (n=35) at randomization. ...Humoral response to KLH was decreased in OCR vs Control. Seroprotection rates …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.",J Immunother Cancer. 2020 Jul;8(2):e000342. doi: 10.1136/jitc-2019-000342.,"PURPOSE: This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast c …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Generation of a Peptide Vaccine Candidate against Falciparum Placental Malaria Based on a Discontinuous Epitope.,Vaccines (Basel). 2020 Jul 18;8(3):E392. doi: 10.3390/vaccines8030392.,We overcame this using a synthetic scaffold to conformationally constrain the SD1 peptide and coupled it to keyhole limpet hemocyanin (KLH). The SD1-KLH conjugate elicited antibodies in mice that cross-reacted with VAR2CSA. This strategy successfully recapitulated a …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Electrochemical nucleation and growth of Pt nanoflower particles on reduced graphite oxide with electrooxidation of glucose.,Anal Methods. 2020 Jul 23;12(28):3617-3625. doi: 10.1039/d0ay00021c.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Immunostimulatory efficacy and protective potential of putative TgERK7 protein in mice experimentally infected by Toxoplasma gondii.,Int J Med Microbiol. 2020 Jul;310(5):151432. doi: 10.1016/j.ijmm.2020.151432. Epub 2020 May 30.,Five predicted peptides of TgERK7 were synthesized and conjugated with KLH and used to analyze the antibody specificity in the sera of immunized mice. ...
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Characterization of natural antigen-specific antibodies from naïve sturgeon serum.,Dev Comp Immunol. 2020 Nov;112:103770. doi: 10.1016/j.dci.2020.103770. Epub 2020 Jul 4.,"Natural antibodies specifically detected hen egg lysozyme (HEL), keyhole limpet hemocyanin (KLH), and several species of pathogenic bacteria. ...Antigen-specific antibodies against KLH, Aeromonas hydrophila and Streptococcus iniae were affinity-fractionated from nai …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Obesity and COVID-19 in New York City: A Retrospective Cohort Study.,Ann Intern Med. 2020 Jul 6:M20-2730. doi: 10.7326/M20-2730. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Rational Design of Hypoallergenic Vaccines: Blocking IgE-binding to Polcalcin Using Allergen-specific IgG Antibodies.,Iran J Allergy Asthma Immunol. 2020 Jun 23;19(3):276-288. doi: 10.18502/ijaai.v19i3.3455.,"The first was a mosaic peptide derivative computationally identified in Che a 3 which was coupled to keyhole limpet hemocyanin (KLH). The second one was a mutant Che a 3, and the other two derivatives included N- and C-terminal halves of Che a 3 that both coupled to KLH …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.,Med Oncol. 2020 Jul 21;37(8):66. doi: 10.1007/s12032-020-01390-w.,There is still no research evaluating the immunoregulatory effects of AZD1775 plus high-dose irradiation (IR) in vivo. T cell killing and CD8+ T cell depletion assays demonstrated that the combination of AZD1775 and IR delayed tumour growth in breast cancer mouse mo …
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.,Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894.,"Inhibition of WEE1 kinase by AZD1775 has shown promising results in clinical cancer trials, but markers predicting AZD1775 response are lacking. Here we analysed AZD1775 response in a panel of human breast cancer (BC) cell lines by global proteome/transcripto …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.,Cancer Res. 2020 Feb 1;80(3):375-376. doi: 10.1158/0008-5472.CAN-19-3587.,"Because ATRX mutations are frequently mutated across a variety of pediatric and adult malignancies, this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inhibitor AZD1775 (adavosertib) for patients whose tumors demonstrate …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.",Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. doi: 10.1158/1078-0432.CCR-20-0219. Epub 2020 Jul 1.,"PURPOSE: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer. ...Future studies sh …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.,Cancer. 2020 Sep 1;126(17):4002-4012. doi: 10.1002/cncr.33048. Epub 2020 Jun 25.,"Patients with MYC amplification or CDKN2A and TP53 co-alterations were allocated to adavosertib (SUKSES protocol C [SUKSES-C]; 7 patients) and those with RICTOR amplification were allocated to vistusertib (SUKSES-D; 4 patients). Alternatively, patients who were without any …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model.,Cancer Cell Int. 2020 Jun 17;20:253. doi: 10.1186/s12935-020-01337-1. eCollection 2020.,"Exploiting this acquired vulnerability; resistant cells exhibited collateral sensitivity for the Wee-1 inhibitor, adavosertib (AZD1775). The combination of ribociclib and adavosertib achieved additional antiproliferative effect exclusively in the cocultures c …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.,Cancer Chemother Pharmacol. 2020 Jul;86(1):97-108. doi: 10.1007/s00280-020-04101-4. Epub 2020 Jun 16.,"METHODS: In this Phase I, open-label, randomized, two-period, two-sequence crossover study, the pharmacokinetics of a single 300 mg adavosertib dose were investigated in fed versus fasted states. ...CONCLUSION: A high-fat meal did not have a clinically relevant effect on t …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.,Sci Rep. 2020 Jun 18;10(1):9930. doi: 10.1038/s41598-020-66018-5.,"This study was conducted to investigate the anti-tumor effects of the WEE1 inhibitor, AZD1775, and the mechanism responsible for its potentiation of sensitivity to olaparib (a PARP inhibitor) via the modulation of DDR in TNBC cells. Our results suggest that AZD1775 …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.,Cancers (Basel). 2020 Jun 9;12(6):1503. doi: 10.3390/cancers12061503.,"Growth of all olaparib-resistant clones isolated could be controlled by WEE1 kinase inhibitor AZD1775, which inactivates the G2 checkpoint. ..."
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.,Cancer Res Treat. 2020 Jul;52(3):945-956. doi: 10.4143/crt.2020.080. Epub 2020 Apr 17.,"RESULTS: AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly increased apoptosis and S phase arrest in sensitive cells. ...In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 exerted more pote …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.,Clin Cancer Res. 2020 Jul 15;26(14):3740-3750. doi: 10.1158/1078-0432.CCR-19-3373. Epub 2020 Mar 27.,Human esophageal cancer xenografts were generated to explore the radiosensitizing effect of AZD1775 in vivo. RESULTS: The IC(50) concentrations of AZD1775 on esophageal cancer cell lines were between 300 and 600 nmol/L. ...AZD1775 significantly abrogated radi …
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.,Cancers (Basel). 2020 Mar 19;12(3):719. doi: 10.3390/cancers12030719.,"Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the activity of many DNA-damaging chemotherapeutics and is currently in clinical development for multiple indications. ...(TNBC012, p < 0.05 combo vs. …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia.,Front Oncol. 2020 Mar 5;10:296. doi: 10.3389/fonc.2020.00296. eCollection 2020.,"We found that AZD1775 resistant cell lines are dependent upon increased HDAC activity for their survival, in part due to increased KDM5A activity. ...Overexpression of c-MYC confers resistance to AZD1775 in cell lines with low baseline expression. Pharmacologic inhi …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol.",BMJ Open. 2020 Mar 16;10(3):e033009. doi: 10.1136/bmjopen-2019-033009.,"This trial explores the associated effect of WEE1 kinase inhibitor adavosertib (AZD1775). METHODS AND ANALYSIS: This phase I dose-finding, open-label, multicentre trial aims to determine the highest safe dose of AZD1775 in combination with cisplatin chemother …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.,J Neurooncol. 2020 May;147(3):531-545. doi: 10.1007/s11060-020-03457-0. Epub 2020 Mar 16.,"The WEE1 inhibitor AZD1775 synergized with inhibitors of nucleotide synthesis, including gemcitabine. AZD1775 with gemcitabine suppressed proliferation and induced apoptosis. Ex vivo modeling demonstrated efficacy in Group 3 medulloblastoma patients, and in vivo mod …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.,Sci Rep. 2020 Feb 11;10(1):2330. doi: 10.1038/s41598-020-58509-2.,"All four precancerous cell lines were highly sensitive to Wee1 inhibition by Adavosertib (AZD1775), while primary keratinocytes tolerated this inhibitor. ..."
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.",Target Oncol. 2020 Feb;15(1):75-84. doi: 10.1007/s11523-020-00701-5.,"BACKGROUND: The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE: This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carbopl …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.,Cancers (Basel). 2020 Jan 28;12(2):306. doi: 10.3390/cancers12020306.,"Subsequent analyses demonstrated potent combination activity between the CHK1/2 inhibitor LY2606268 (prexasertib), which eliminates a G2 checkpoint, and the WEE1 inhibitor AZD1775 (adavosertib), which promotes M-phase entry, in induction of DNA damage, mitotic catas …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma.,Ther Adv Hematol. 2020 Jan 20;11:2040620719898373. doi: 10.1177/2040620719898373. eCollection 2020.,"RESULTS: Treatment with either RT or CHOP led to enhanced sensitivity to AZD1775 in several DLBCL cell lines. Treatment of cells with AZD1775 induced unscheduled mitotic progression, resulting in abnormal cell cycle distribution in combination with RT or CHOP treatm …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.,Pediatr Blood Cancer. 2020 May;67(5):e28098. doi: 10.1002/pbc.28098. Epub 2020 Jan 23.,AZD1775 is a WEE1 inhibitor that is in clinical development for children and adults with cancer. METHODS: AZD1775 was tested using a dose of 120 mg/kg administered orally for days 1 to 5. Irinotecan was administered intraperitoneally at a dose of 2.5 mg/kg for days …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia.",Cancers (Basel). 2020 Aug 17;12(8):2312. doi: 10.3390/cancers12082312.,"Trabectedin (ET743) and lurbinectedin (PM01183) limit the production of inflammatory cytokines that are elevated during cancer cachexia. ...Since PM01183 extended the animal survival more than ET743, we analyzed PM01183 further. In tibialis anterior of …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.",Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27.,"Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. ...Treatment consisted of 3·2 mg/m(2) lurbinectedin …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.,Lancet Oncol. 2020 May;21(5):605-607. doi: 10.1016/S1470-2045(20)30097-8. Epub 2020 Mar 27.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.,Cancer Immunol Immunother. 2020 May;69(5):813-824. doi: 10.1007/s00262-020-02513-y. Epub 2020 Feb 13.,"In this study, we aimed to evaluate the activity of Lurbinectedin on circulating mononuclear cells from CLL patients and to determine whether Lurbinectedin could affect the cross-talk between B-CLL cells and the tumor microenvironment. ...Our findings encourage furt …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.,Eur J Cancer. 2020 Feb;126:21-32. doi: 10.1016/j.ejca.2019.10.021. Epub 2019 Dec 31.,"Lurbinectedin is a new anticancer agent under investigation. The primary objective of this three-arm, phase II study was to determine the disease control rate (DCR = ORR + stable disease [SD]) at 24 weeks of lurbinectedin alone or with chemotherapy in STS. ...Study …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.,Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin.,Angew Chem Int Ed Engl. 2019 Mar 18;58(12):3972-3975. doi: 10.1002/anie.201900035. Epub 2019 Feb 14.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.,Mol Cancer Res. 2019 Mar;17(3):773-782. doi: 10.1158/1541-7786.MCR-18-0575. Epub 2018 Dec 14.,"Here we show that R-loops play an important role in the cellular response to trabectedin (ET743), an anticancer drug from marine origin and its derivative lurbinectedin (PM01183). ...In yeast, trabectedin and lurbinectedin increased the presence of Rad52 foci …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.",Invest New Drugs. 2019 Oct;37(5):818-827. doi: 10.1007/s10637-018-0686-6. Epub 2018 Oct 30.,Mouse xenografts of cervical cancer revealed that lurbinectedin significantly inhibits tumor growth. The growth-inhibitory effect of lurbinectedin was greater than that of cisplatin and paclitaxel. ...Conclusions Lurbinectedin is highly effective on uterine c …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.,Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.,"Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Lurbinectedin for BRCA-mutated advanced breast cancer.,Lancet Oncol. 2018 Nov;19(11):e582. doi: 10.1016/S1470-2045(18)30737-X. Epub 2018 Sep 27.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.,J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.,"PURPOSE: This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. ...In vivo, sensitivity to cisplatin and lurbinectedin was evidenced …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.,Hematol Oncol. 2019 Feb;37(1):96-102. doi: 10.1002/hon.2557. Epub 2018 Dec 5.,"Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3 + 3 study design. ...Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissio …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.",Clin Pharmacokinet. 2019 Mar;58(3):363-374. doi: 10.1007/s40262-018-0701-2.,"The potential influence of demographic, co-treatment, and laboratory characteristics on lurbinectedin pharmacokinetics was evaluated. ...Co-administration of cytochrome P450 3A inhibitors increased lurbinectedin exposure...."
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.,J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.,Lurbinectedin was eluted from the columns using tert-butyl methyl ether (TBME). Urine was first diluted in plasma and lurbinectedin was extracted from this matrix by liquid-liquid extraction using TBME. ...The method was developed to support a mass balance study in …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Targeting DNA damage in SCLC.,Lung Cancer. 2017 Dec;114:12-22. doi: 10.1016/j.lungcan.2017.10.006. Epub 2017 Oct 16.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.,Ann Oncol. 2017 Oct 1;28(10):2559-2566. doi: 10.1093/annonc/mdx357.,"BACKGROUND: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. ...RESULTS: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose was the RD. In relapsed SCLC, treatment tolerance at the RD wa …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.,Immunotherapy. 2017 Sep;9(10):805-817. doi: 10.2217/imt-2017-0046.,"AIM: To evaluate the ability of PM01183 to eliminate myeloid-derived suppressor cells (MDSCs). MATERIALS & METHODS: The effect of PM01183 on MDSCs, NK cells and CD8(+) T cells was examined in vitro and in vivo. ...CONCLUSION: PM01183 exhibits strong inhib …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.,Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.,"Ascites completely abolished the activity of lurbinectedin at up to 10nM (in regular medium corresponds to the IC90), strongly reduced that of trabectedin, inhibited the cellular uptake of lurbinectedin and, to a lesser extent, that of trabectedin. ...KD values are …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.,Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.,"Similar findings were observed when a lurbinectedin-resistant tumour variant was used, indicating a direct effect of lurbinectedin on the tumour microenviroment. ...These findings were supported by the strong inhibition of genes of the Rho-GTPase family in lurbin …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.,Leukemia. 2020 Aug 20. doi: 10.1038/s41375-020-01010-6. Online ahead of print.,"Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/refractory CLL. We conducted an investigator-initiated, phase 1b/2 study of duvelisib + FCR (DFCR) as initial treatment for CLL patients aged ≤65. A standard 3 + 3 design included two dose levels of  …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.,Expert Opin Drug Saf. 2020 Aug 25:1-16. doi: 10.1080/14740338.2020.1802424. Online ahead of print.,
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Copanlisib in the treatment of non-Hodgkin lymphoma.,Future Oncol. 2020 Sep;16(26):1947-1955. doi: 10.2217/fon-2020-0195. Epub 2020 Jul 13.,"The two other PI3k inhibitors approved by the US FDA in this setting are idelalisib and duvelisib. In this review, we compare the efficacy and adverse event profile of these different PI3K inhibitors and discuss the advantages and challenges of using copanlisib along with …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.,Blood Adv. 2020 Jul 14;4(13):3072-3084. doi: 10.1182/bloodadvances.2020001800.,"The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). ...Here, …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.,Int J Hematol. 2020 Jul 1. doi: 10.1007/s12185-020-02929-3. Online ahead of print.,"Duvelisib was administered orally twice daily at 25 mg in 28-day cycles. Seven patients, comprising 4 with follicular lymphoma (FL), 2 with diffuse large B-cell lymphoma, and 1 with mantle cell lymphoma (MCL) were enrolled. ...Duvelisib was well tolerated in Japanes …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.,Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16808. Online ahead of print.,"In the relapsed or Cy-refractory setting, alemtuzumab (n = 4) and pentostatin (n = 3) had an ORR of 50% and 66%, respectively, while duvelisib induced a long-term response in one patient. ...Prospective studies evaluating pentostatin, alemtuzumab and novel agents, such as …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.,Sci Rep. 2020 Jun 1;10(1):8867. doi: 10.1038/s41598-020-65637-2.,"Here, we found that both PI3K-α and -δ isoforms are abundantly expressed in our MCC cell lines and clinical samples; we therefore examined antitumor efficacy across a panel of five PI3K inhibitors with distinctive isoform-specificities, including idelalisib (PI3K-δ), copanlisib ( …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,"The regulation and function of CD20: an ""enigma"" of B-cell biology and targeted therapy.",Haematologica. 2020 Jun;105(6):1494-1506. doi: 10.3324/haematol.2019.243543.,"Current efforts to combine anti-CD20 monoclonal antibodies with BCR signaling inhibitors targeting BTK or PI3K (ibrutinib, acalabrutinib, idelalisib, duvelisib) or BH3-mimetics (venetoclax) lead to the necessity to better understand both the mechanisms of regulation and th …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.,J Pharm Biomed Anal. 2020 Aug 5;187:113355. doi: 10.1016/j.jpba.2020.113355. Epub 2020 May 11.,"Selected reaction monitoring (SRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 416.88 → 281.88 for duvelisib, and m/z 553.09 → 436.01 for IS, respectively. The assay was successfully established in the calibration range from 0.5 to 30 …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.,J Immunol. 2020 Jul 1;205(1):78-89. doi: 10.4049/jimmunol.2000043. Epub 2020 May 15.,"Idelalisib (PI3Kδ), alpelisib (PI3Kα), duvelisib (PI3Kδ/γ), and copanlisib (pan-PI3K) have recently been approved for use in cancer treatment. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.,Curr Treat Options Oncol. 2020 Apr 30;21(6):51. doi: 10.1007/s11864-020-00746-8.,"With three agents now FDA approved for the treatment of relapsed and refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), idelalisib, copanlisib, and duvelisib, we aim to review the pivotal trials leading to their approval as well as their clinical applications according …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,[Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].,Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):708-712. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.060.,"To date, the BTK inhibitor Ibrutinib, PI3K inhibitors Idelalisib and Duvelisib have been approved for CLL treatment, and some novel inhibitors are still in clinical trials. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Duvelisib for the treatment of chronic lymphocytic leukemia.,Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15.,"AREAS COVERED: This review provides analysis of the mechanism of action of duvelisib and includes the rationale for the use of double inhibition. The authors also give their clinical experience with duvelisib. Overall, despite the high efficacy of the drug, some con …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.,Curr Treat Options Oncol. 2020 Mar 13;21(4):24. doi: 10.1007/s11864-020-0715-5.,"Treatment landscape of chronic lymphocytic leukemia (CLL) has changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway (ibrutinib, acalabrutinib, idelalisib and duvelisib) and the inhibitor of the anti-apoptotic protein BCL-2 (venetoclax …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Biomarkers of genome instability in normal mammalian genomes following drug-induced replication stress.,Environ Mol Mutagen. 2020 Feb 20. doi: 10.1002/em.22364. Online ahead of print.,"Here, we show that drug-induced replication stress leads to increased genome instability in vitro using proliferating primary human cells as well as in vivo in rat bone marrow (BM) and duodenum (DD). p53-binding protein 1 (53BP1, biomarker of DNA damage repair) nuclear bodies wer …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.,Clin Cancer Res. 2020 May 1;26(9):2096-2103. doi: 10.1158/1078-0432.CCR-19-3061. Epub 2020 Jan 21.,We report results from patients with progressive disease (PD) after ofatumumab who crossed over to duvelisib in the DUO trial. PATIENTS AND METHODS: Patients with radiographically confirmed PD after ofatumumab received duvelisib 25 mg twice daily in 28-day cycles un …
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Isoform-Selective PI3K Inhibitors for Various Diseases.,Curr Top Med Chem. 2020;20(12):1074-1092. doi: 10.2174/1568026620666200106141717.,"Idelalisib, Copanlisib, Duvelisib, and Alpelisib were approved by the FDA for the treatment of different types of cancer and several other PI3K inhibitors are currently under active clinical development. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.,Cancer J. 2019 Nov/Dec;25(6):428-435. doi: 10.1097/PPO.0000000000000406.,"These 4 agents include the Bruton tyrosine kinase inhibitor ibrutinib, the B-cell leukemia/lymphoma-2 inhibitor venetoclax, and the phosphatidylinositol-3 kinase inhibitors idelalisib and duvelisib. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,"INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).",ACS Med Chem Lett. 2019 Oct 17;10(11):1554-1560. doi: 10.1021/acsmedchemlett.9b00334. eCollection 2019 Nov 14.,"The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in other PI3Kδ inhibitors, such as idelalisib (1), duvelisib (2), and INCB040093 (3, dezapelisib). ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.,Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032.,
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.",Pharmacol Ther. 2020 Jun;210:107518. doi: 10.1016/j.pharmthera.2020.107518. Epub 2020 Feb 26.,"We also outline the transition from preclinical to clinical studies, as well as its relationships with other clinical candidates (AZD6738, VX-803 [M4344], and BAY1895344). ..."
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?,Pharmacol Ther. 2020 Mar;207:107450. doi: 10.1016/j.pharmthera.2019.107450. Epub 2019 Dec 11.,"Targeting ATR is the focus of many oncology drug pipelines with a number of potent, selective ATR inhibitors developed, four (M6620, M4344, AZD6738 and BAY1895344) are currently in clinical development. ..."
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.,J Hematol Oncol. 2019 Apr 24;12(1):43. doi: 10.1186/s13045-019-0733-6.,"Preclinical and clinical data from early-phase trials on three ATR inhibitors (M6620, AZD6738, and BAY1895344), either as monotherapy or in combination, were reviewed. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.,Cytokine X. 2020 Dec;2(4):100035. doi: 10.1016/j.cytox.2020.100035. Epub 2020 Sep 2.,"We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.,Am J Hematol. 2020 Sep 7. doi: 10.1002/ajh.25992. Online ahead of print.,Anti-IL-6 therapy with siltuximab is the only FDA- or EMA-approved treatment based on efficacy and safety in multiple studies. ...NCCN currently recommends siltuximab first-line for iMCD except for patients considered to have HV histopathology. We investigated wheth …
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis.,Int J Mol Sci. 2020 Aug 31;21(17):E6290. doi: 10.3390/ijms21176290.,
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.,Pulm Ther. 2020 Aug 25:1-17. doi: 10.1007/s41030-020-00126-5. Online ahead of print.,"., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results. Potential newer agents (e.g., Janus kinase inhibitor such as ruxolitinib, baricitinib, fedratinib) are likely to be investigated in clinical trials. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.,Infect Dis Ther. 2020 Aug 12. doi: 10.1007/s40121-020-00326-1. Online ahead of print.,"In an effort to reduce the severity of organ dysfunction, including respiratory insufficiency, monoclonal antibodies (Mabs) that block the interleukin-6 receptor, such as tocilizumab, sarilumab, and siltuximab, are under investigation for the treatment of COVID-19. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.,Cureus. 2020 Jul 2;12(7):e8967. doi: 10.7759/cureus.8967.,"Therefore, treatment with agents that bind to IL-6 (such as siltuximab) or block the IL-6 receptor (such as tocilizumab) has been used. ...We postulate that her siltuximab therapy blocked the IL-6-associated fever and constitutional symptoms that normally are a hall …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.,J Pharm Pharm Sci. 2020;23:259-277. doi: 10.18433/jpps31346.,"., the use of remdesivir, lopinavir, ritonavir, umifenovir (arbidol), oseltamivir, ganciclovir, favipiravir, darunavir, hydroxychloroquine, chloroquine, colchicine, azithromycin, anakinra, canakinumab, tocilizumab, siltuximab, sarilumab, Type 1 interferon, interferon β-1a, …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.,Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7475-7484. doi: 10.26355/eurrev_202007_21916.,"A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Pharmaco-Immunomodulatory Therapy in COVID-19.,Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z.,"Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, inf …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Siltuximab.,2020 Jul 20. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–.,"No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein molecule with a molecular weight of about 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is proba …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study.",Lancet Child Adolesc Health. 2020 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2. Epub 2020 Jun 25.,"Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.,Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13473. Online ahead of print.,
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,"Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.",BioDrugs. 2020 Aug;34(4):415-422. doi: 10.1007/s40259-020-00430-1.,"It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?,Pharmaceut Med. 2020 Aug;34(4):223-231. doi: 10.1007/s40290-020-00342-z.,"Considering the proven role of cytokine dysregulation in causing this hyperinflammation in the lungs with IL-6 being a key driver, particularly in seriously ill COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like the IL-6 inhibitors toc …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Additive treatment considerations in COVID-19-The clinician's perspective on extracorporeal adjunctive purification techniques.,Artif Organs. 2020 Jun 9:10.1111/aor.13748. doi: 10.1111/aor.13748. Online ahead of print.,"Multiple therapeutic strategies, including antibody therapies (such as Tocilizumab, Sarilumab, Siltuximab), therapeutic plasma exchange (TPE), and blood purification techniques for direct removal of cytokines, including filtration, dialysis (diffusion), and adsorption are …"
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Long-Term Survival of a Patient with Metastatic Ovarian Cancer and Local Recurrence of Rectal Cancer].,Gan To Kagaku Ryoho. 2020 Jan;47(1):162-164.,"She received adjuvant therapy with UFT. Three years after the primary resection, metastasis to the right ovary and local recurrence were diagnosed. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.,Eur J Hosp Pharm. 2020 Sep;27(5):297-298. doi: 10.1136/ejhpharm-2020-002322. Epub 2020 Jun 4.,"The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. ...Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.,Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.,"The experimental arms consist of Anakinra alone (anti-IL-1 binding the IL-1 receptor), Siltuximab alone (anti-IL-6 chimeric antibody), a combination of Siltuximab and Anakinra, Tocilizumab alone (humanised anti-IL-6 receptor antibody) or a combination of Anakinra wi …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?,Br J Pharmacol. 2020 Aug;177(16):3635-3645. doi: 10.1111/bph.15137. Epub 2020 Jul 5.,"PARPi may potentiate the effectiveness of tocilizumab, anakinra, sarilumab, adalimumab, canakinumab or siltuximab therapy. The evidence suggests that PARPi would benefit COVID-19 patients and trials should be undertaken...."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.,J Med Virol. 2020 May 21:10.1002/jmv.26038. doi: 10.1002/jmv.26038. Online ahead of print.,"METHODS: We performed a systematic search of PubMed, Embase, and Medline from 22nd April 2020 and again on 27th April 2020 using the following search terms alone or in combination: ""COVID-19,"" ""coronavirus,"" ""SARS-CoV-2,"" ""COVID,"" ""anti-interleukin-6 receptor antibodies,"" ""anti-I …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.,J Immunother Cancer. 2020 May;8(1):e000930. doi: 10.1136/jitc-2020-000930.,
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,"Advances in urologic oncology ""OncoForum"": The best of 2019.",Actas Urol Esp. 2020 Sep 15:S0210-4806(20)30153-4. doi: 10.1016/j.acuro.2020.06.007. Online ahead of print.,"Cabazitaxel has demonstrated a survival benefit in patients with metastatic CRPC, while olaparib showed anti-tumor activity after chemotherapy in those tumors with mutations in DNA repair genes. ...In metastatic CRPC, cabazitaxel and olaparib (targeting mutations) a …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.",Lancet Oncol. 2020 Sep 11:S1470-2045(20)30449-6. doi: 10.1016/S1470-2045(20)30449-6. Online ahead of print.,"FINDINGS: Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). ...Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patie …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability.,Pharm Dev Technol. 2020 Sep 16:1-8. doi: 10.1080/10837450.2020.1818780. Online ahead of print.,"Pluronic (Poloxomer) micelles can solubilize cabazitaxel (CTX), a second-generation taxane, and then be subjected to low-temperature ""surfactant-stripping"" to selectively remove loose and free surfactant, thereby increasing the drug-to-surfactant ratio. We previously found …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Taxanes.,2020 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Paclitaxel was the first compound in this chemical group to be introduced into clinical use and was initially isolated from the bark of the Western yew …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Cabazitaxel.,2020 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations, but has no …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo/photodynamic efficacy of patient-derived melanoma.,J Control Release. 2020 Sep 1;328:325-338. doi: 10.1016/j.jconrel.2020.08.062. Online ahead of print.,"Ligation of anticancer cabazitaxel (CTX) drugs via a reactive oxygen species-activatable thioketal linkage generates a dimeric TKdC prodrug, and subsequent coassembly with a photosensitizer, chlorin e6 (Ce6), forms colloidal-stable nanoassemblies (termed psTKdC NAs). ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Molecular docking analysis of docetaxel analogues as duel lipocalin 2 inhibitors.,Bioinformation. 2020 Jun 30;16(6):438-443. doi: 10.6026/97320630016438. eCollection 2020.,"We document 10 analogues (4Deacetyltaxol, 7Acetyltaxol, Cabazitaxel, Cephalomannine, Docetaxal, Deacetyltaxol, Docetaxeltrihydrate, Ortataxel, Paclitaxel, Taxoline) having optimal binding with Lipocalin 2 in comparison with Docetaxel. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.,Anticancer Res. 2020 Sep;40(9):5255-5261. doi: 10.21873/anticanres.14529.,"RESULTS: The median number of cabazitaxel infusions was 4 (range=1-18). In general, cabazitaxel was well-tolerated. The fraction of patients alive and without progression after 3 months of treatment was 54% (14/26). ...CONCLUSION: Cabazitaxel holds promise as …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.,Anticancer Res. 2020 Sep;40(9):5091-5095. doi: 10.21873/anticanres.14512.,"MATERIALS AND METHODS: Cabazitaxel resistance was induced in the castration-resistant prostate cancer cell line, 22Rv1-CR. In vitro and in vivo models were used to test the efficacy of YM155 and cabazitaxel. ...CONCLUSION: Inhibition of survivin by YM155 overcomes …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Improved antitumor activity and tolerability of cabazitaxel derived remote-loading liposomes.,Int J Pharm. 2020 Aug 30;589:119814. doi: 10.1016/j.ijpharm.2020.119814. Online ahead of print.,"Two weak-base cabazitaxel derivatives were synthesized, and named CN and CN2. CN exhibited higher cytotoxic effects compared to CN2, and was selected for further study. ...When compared to the commercial formulation of cabazitaxel, JEVTANA®, CN-LPs showed less syste …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.,Sci Adv. 2020 Jul 15;6(29):eabb0616. doi: 10.1126/sciadv.abb0616. eCollection 2020 Jul.,"Here, we report a hybrid nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC to achieve an optimal antitumor effect. ...Encapsulation of cabazitaxel in the nanocomplex enhances the activity of the IKBKE siRNA. The hybrid nanocomplex provides a novel an …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.,Int J Nanomedicine. 2020 Jul 29;15:5333-5344. doi: 10.2147/IJN.S258856. eCollection 2020.,"PURPOSE: Cabazitaxel (CBZ) is a new taxane-based antitumor drug approved by the FDA for the treatment of prostate cancer, especially for patients with advanced prostate cancer for whom docetaxel is ineffective or causes aggravation. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Ultrasound-Mediated Delivery of Chemotherapy into the Transgenic Adenocarcinoma of the Mouse Prostate Model.,Ultrasound Med Biol. 2020 Aug 12:S0301-5629(20)30296-9. doi: 10.1016/j.ultrasmedbio.2020.07.004. Online ahead of print.,We used two phenotypes of the spontaneous transgenic adenocarcinoma of the mouse prostate (TRAMP) model to evaluate if US + MB could enhance the therapeutic efficacy of cabazitaxel (Cab). ...
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Aurora A inhibitor TAS-119 enhances antitumor efficacy of taxanes in vitro and in vivo: preclinical studies as guidance for clinical development and trial design.,Mol Cancer Ther. 2020 Aug 11:molcanther.0036.2020. doi: 10.1158/1535-7163.MCT-20-0036. Online ahead of print.,"The same TAS-119 concentration enhanced the cell growth inhibitory activity of three clinically approved taxanes, paclitaxel, docetaxel, and cabazitaxel. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Microfluidic self-assembly of high cabazitaxel loading albumin nanoparticles.,Nanoscale. 2020 Aug 28;12(32):16928-16933. doi: 10.1039/c9nr10941b. Epub 2020 Aug 10.,"Cabazitaxel (CTX) is a promising anticancer drug. In this study, CTX-loaded human serum albumin (HSA) nanoparticles (MF-NPs-CTX) were prepared by a microfluidic (MF) method and were evaluated for tumor inhibition in PC-3 and HeLa cells in vitro and in vivo. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).,Eur Urol Oncol. 2020 Aug 2:S2588-9311(20)30093-6. doi: 10.1016/j.euo.2020.07.002. Online ahead of print.,"DESIGN, SETTING, AND PARTICIPANTS: Thirty-two men with progressive mCRPC previously treated with taxane-based chemotherapy (91% treated with both docetaxel and cabazitaxel) and abiraterone and/or enzalutamide were enrolled in this phase I dose escalation study with phase I …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.,IJU Case Rep. 2020 Feb 14;3(2):62-64. doi: 10.1002/iju5.12144. eCollection 2020 Mar.,INTRODUCTION: We report the case of a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high who was treated with pembrolizumab after cabazitaxel administration. ...
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.,Prostate. 2020 Jul 31. doi: 10.1002/pros.24048. Online ahead of print.,"After failing second HT, 90 patients were assigned for docetaxel-alone (group A), 33 patients received carboplatin plus docetaxel (group B), while 27 patients received cabazitaxel-alone (Group C). ...We report a Hazard Ratio of 3.1 (95% CI, 1.31-7.35; P = .0037) between pa …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer.,Semin Oncol Nurs. 2020 Aug;36(4):151047. doi: 10.1016/j.soncn.2020.151047. Epub 2020 Jul 22.,"Since then, drugs such as docetaxel, abiraterone, enzalutamide, cabazitaxel, radium-223 dichloride, and (not available in Australia) sipuleucel-T have all demonstrated efficacy in prolongation of survival in castrate-resistant prostate cancer, and improvement in cancer-rel …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study.,BMC Cancer. 2020 Jul 13;20(1):649. doi: 10.1186/s12885-020-07131-6.,BACKGROUND: The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m(2) in Japan and Europe. ...METHODS: We compared the safety and efficacy of cabazitaxel between patients who received cabazitaxel at starting do …
2020-09-23T05:55:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=GD2L-KLH/QS-21&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.,"This issue focuses on the following selection of drugs: ABI-007, adalimumab, adefovir dipivoxil, alefacept, alemtuzumab, 3-AP, AP-12009, APC-8015, L-Arginine hydrochloride, aripiprazole, arundic acid, avasimibe; Bevacizumab, bivatuzumab, BMS-181176, BMS-184476, BMS-188797, bortez …"
2020-09-23T05:55:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=GD2L-KLH/QS-21&sort=date&size=20,Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.,Clin Cancer Res. 2003 Nov 1;9(14):5214-20.,"Groups of 6 patients were entered at three dose levels (3, 10, or 30 micro g) of GD2 lactone (GD2L) in vaccines containing GD2L-KLH plus the immunological adjuvant QS-21. ...CONCLUSIONS: GD2L-KLH conjugate vaccine plus adjuvant …"
2020-09-23T05:55:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=RGX-104&sort=date&size=20,LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells.,Biochem Biophys Res Commun. 2020 Jul 23;528(2):330-335. doi: 10.1016/j.bbrc.2020.04.137. Epub 2020 May 22.,"Here, we report for the first time that LXR agonists, GW3965 and RGX-104, radiosensitized NSCLC in a subcutaneous homograft murine model. ...Treatment with RGX-104 greatly promoted MDSC apoptosis in vitro. Depleting MDSC activated cytotoxic T lymphocyt …"
2020-09-23T05:55:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=RGX-104&sort=date&size=20,Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy.,J Control Release. 2020 Jan 10;317:43-56. doi: 10.1016/j.jconrel.2019.11.011. Epub 2019 Nov 20.,"Here we have designed a dual-pH-sensitivity conjugated micelle system (PAH/RGX-104@PDM/PTX) that could deliver liver-X nuclear receptor (LXR) agonist RGX-104 and paclitaxel (PTX) to the perivascular region and tumor cells, respectively. Upon arrival at …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.,Anticancer Res. 2020 Sep;40(9):5141-5149. doi: 10.21873/anticanres.14517.,"RESULTS: Both TMZ and AZD7762 induced concentration- and time-dependent cytotoxic effects, and combined TMZ and AZD7762 (TMZ+AZD) caused synergistic cytotoxic effects in glioma cells (p<0.05). AZD7762 suppressed the O(6)-methylguanine-DNA-methyltransferase …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.",Radiat Environ Biophys. 2020 Aug 28. doi: 10.1007/s00411-020-00867-6. Online ahead of print.,"Cells pretreated with the CHK1/CHK2 inhibitor AZD7762, Honokiol or Tunicamycin were irradiated with low-LET X-rays and high-LET carbon ions. ...Our results revealed that AZD7762, Honokiol and Tunicamycin demonstrated low cytotoxicity to NSCLC cells and a pronounced …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.,Cancers (Basel). 2020 Jun 29;12(7):1726. doi: 10.3390/cancers12071726.,"The antitumor efficacy of CHK1 inhibitors (PF477736, AZD7762, LY2606368) and PI3K inhibitors (BYL719, GDC0941, GSK1059615) was investigated in OSCC cell lines and PDX models. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation.,Oncogene. 2020 May;39(22):4344-4357. doi: 10.1038/s41388-020-1300-x. Epub 2020 Apr 25.,"The Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in multiple cell lines and, we find that this therapeutic combination promotes increased micronuclei formation in vitro and subsequently drives increased type I in …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.,Biomaterials. 2020 Jul;248:120032. doi: 10.1016/j.biomaterials.2020.120032. Epub 2020 Apr 11.,Antibody drug conjugates honed in on tumor overexpressed cell surface receptors with high specificity but lacked efficacy when conjugated to the DNA damage checkpoint kinase inhibitor AZD7762. ...
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells.,Cancer Cell Int. 2019 Jul 27;19:195. doi: 10.1186/s12935-019-0896-9. eCollection 2019.,"BACKGROUND: AZD7762 is a checkpoint kinase 1 (Chk 1) inhibitor, which has been reported to sensitize many tumor cells to DNA damage. ...The clinical application of AZD7762 as an adjuvant in the chemotherapy of osteosarcoma should be further explored...."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer.,FEBS Lett. 2019 Jul;593(14):1827-1836. doi: 10.1002/1873-3468.13461. Epub 2019 Jun 7.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.,Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.,"AZD6738 exerted a strong synergistic cytotoxic effect in combination with both AZD7762 and AZD1775 in the 2 lymphoma subtypes regardless of their TP53, MYC, and ATM mutational status. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.,J Thorac Oncol. 2019 Jun;14(6):1032-1045. doi: 10.1016/j.jtho.2019.01.028. Epub 2019 Feb 14.,"The effect was regulated in part through activation of caspase 2 and downregulation of E2F transcription factor 1 (E2F1). Furthermore, Chk1 inhibitors prexasertib and AZD7762 enhanced cisplatin antitumor activity and overcame cisplatin resistance in SCLC preclinical …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.,Toxicol Appl Pharmacol. 2019 Feb 15;365:71-83. doi: 10.1016/j.taap.2019.01.005. Epub 2019 Jan 8.,"The ROS scavenger N-acetylcysteine (NAC) and the specific p38 inhibitor SB203580 reversed the effects of A-macB on the p38 network and thus rescued ESCC cells from apoptosis. ...Taken together, A-macB is a promising lead compound for ESCC and exerts synergistic anti-cancer …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.,Clin Cancer Res. 2019 Jan 15;25(2):856-867. doi: 10.1158/1078-0432.CCR-18-1469. Epub 2018 Oct 23.,"We assessed abiraterone acetate and Chk1 inhibitors (GDC-0575 and AZD7762) efficacies, either alone or in combination, on cell lines grown in vitro and in vivo. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells.,Diabetes. 2018 Nov;67(11):2319-2328. doi: 10.2337/db18-0204. Epub 2018 Aug 13.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Identification of Novel Mycobacterial Inhibitors Against Mycobacterial Protein Kinase G.,Front Microbiol. 2018 Jul 12;9:1517. doi: 10.3389/fmicb.2018.01517. eCollection 2018.,"We found that four compounds, namely AZD7762, R406, R406-free base, and CYC116, inhibited PknG activities. AZD7762, R406, and R406-free base promoted transfer of mycobacteria to lysosomes. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.",Int J Oncol. 2018 Sep;53(3):1001-1012. doi: 10.3892/ijo.2018.4481. Epub 2018 Jul 13.,"Using AZD7762, an inhibitor of checkpoint kinase (Chk) 1 and 2, the present study examined its effect on mammary tumor cells in addition to bone cells (osteoclasts, osteoblasts and osteocytes), using monolayer cell cultures and three-dimensional (3D) cell spheroids. …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.,Oncotarget. 2018 May 25;9(40):26064-26071. doi: 10.18632/oncotarget.25436. eCollection 2018 May 25.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn.",Biochem Pharmacol. 2018 Aug;154:270-277. doi: 10.1016/j.bcp.2018.05.012. Epub 2018 May 17.,The aim of this study was to investigate the anti-allergic effects of 3-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-thiophenecarboxamide (AZD7762) in vitro and in vivo. AZD7762 inhibited the antig …
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.,Cancer Lett. 2018 Aug 28;430:34-46. doi: 10.1016/j.canlet.2018.05.011. Epub 2018 May 16.,Targeting of oncogene-driven replicative stress as therapeutic option for high-risk medullobastoma was assessed using a panel of medulloblastoma cells differing in their c-Myc expression [i.e. group SHH (c-Myc low) vs. group 3 (c-Myc high)]. ...The enhanced sensitivity of …
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.,Cancer Lett. 2018 Aug 1;428:104-116. doi: 10.1016/j.canlet.2018.04.029. Epub 2018 Apr 26.,"Moreover, using qHTCS we identified two Chk1 inhibitors (PF-477736 and AZD7762) that re-sensitize resistant cells to cisplatin. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells.,Nat Commun. 2018 Apr 3;9(1):1303. doi: 10.1038/s41467-018-03760-5.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer.",Cancer Biol Ther. 2018 Jul 3;19(7):609-621. doi: 10.1080/15384047.2018.1449613. Epub 2018 May 8.,"A-macB activated the Chk1/2-Cdc25C-Cdc2/cyclin B1 axis to induce G2/M phase arrest. AZD7762 abrogated the function of Chk1/2, abolished the G2/M delay and enhanced the cytotoxicity of A-macB. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.,Pharmacol Res. 2020 Aug 3;161:105092. doi: 10.1016/j.phrs.2020.105092. Online ahead of print.,"It is therefore of great interest to investigate CXCR4/CXCR7/CXCL12 modulators in clinical development, with several CXCR4 and CXCL12 modulators such as plerixafor, ulocuplumab, balixafortide, and olaptesed pegol having already reached this stage. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.,Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.,"PURPOSE: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. ...Using a 3+3 design on both arms of the trial, ulocuplumab's dose was escalated to a maximum of 10 mg/ …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,What is new in the treatment of Waldenstrom macroglobulinemia?,Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7.,"., ulocuplumab), among others. It is certainly an exciting time for WM therapy development with novel and promising treatment options in the horizon...."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Immunotherapy for small-cell lung cancer: emerging evidence.,Future Oncol. 2016 Apr;12(7):931-43. doi: 10.2217/fon-2015-0012. Epub 2016 Feb 17.,"Immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, durvalumab, tremelimumab and ulocuplumab are at the forefront of immunotherapy and have achieved approvals for certain cancer types, including melanoma (ipilimumab, nivolumab and pembrolizumab), non …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.,Oncotarget. 2016 Jan 19;7(3):2809-22. doi: 10.18632/oncotarget.6465.,"We found that Ulocuplumab (BMS-936564) inhibited CXCL12 mediated CXCR4 activation-migration of CLL cells at nanomolar concentrations. ...However, Ulocuplumab (BMS-936564) but not AMD3100 induced apoptosis in CLL at nanomolar concentration …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.,Cell Rep. 2015 Jul 28;12(4):622-35. doi: 10.1016/j.celrep.2015.06.059. Epub 2015 Jul 16.,"Ulocuplumab, a monoclonal anti-CXCR4 antibody, inhibited MM cell dissemination, supported by suppression of the CXCR4-driven EMT-like phenotype. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.,Clin Cancer Res. 2013 Jan 15;19(2):357-66. doi: 10.1158/1078-0432.CCR-12-2333. Epub 2012 Dec 4.,"RESULTS: BMS-936564/MDX-1338 is a fully human IgG(4) monoclonal antibody that specifically recognizes human CXCR4. In vitro studies show that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 binding to CXCR4-expressing cells, and i …"
2020-09-23T05:55:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=SGN-LIV1A&sort=date&size=20,Antibody-drug conjugates in triple negative breast cancer.,Future Oncol. 2018 Oct;14(25):2651-2661. doi: 10.2217/fon-2018-0131. Epub 2018 Sep 3.,"This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA...."
2020-09-23T05:55:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=SGN-LIV1A&sort=date&size=20,SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.,Mol Cancer Ther. 2014 Dec;13(12):2991-3000. doi: 10.1158/1535-7163.MCT-13-0896. Epub 2014 Sep 24.,"In this article, we describe a novel antibody-drug conjugate (ADC; SGN-LIV1A), targeting the zinc transporter LIV-1 (SLC39A6) for the treatment of metastatic breast cancer. ...These results support the clinical evaluation of SGN-LIV1A as a novel therap …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.,Urol Oncol. 2020 Sep 18:S1078-1439(20)30370-7. doi: 10.1016/j.urolonc.2020.08.003. Online ahead of print.,"The phase 3 PROSPER, SPARTAN, and ARAMIS trials for enzalutamide, apalutamide, and darolutamide, the 3 approved androgen receptor inhibitors for men with nmCRPC, were all associated with increased metastasis-free survival in patients with metastatic castration-resistant pr …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Advances in urologic oncology ""OncoForum"": The best of 2019.",Actas Urol Esp. 2020 Sep 15:S0210-4806(20)30153-4. doi: 10.1016/j.acuro.2020.06.007. Online ahead of print.,"The benefit of enzalutamide and apalutamide associated with castration has been confirmed in M1 PCa patients, regardless of disease volume. ...The arrival of new agents for advanced urothelial carcinoma should be highlighted, and the efficacy of enzalutamide and apaluta …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.,Drugs. 2020 Sep 15. doi: 10.1007/s40265-020-01401-0. Online ahead of print.,"Apalutamide (Erleada(®)) is an oral selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. ...Although mature OS data are awaited with interest, the addition of apalutamide to ADT extends the treatment options availabl …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.",Int J Clin Oncol. 2020 Sep 14. doi: 10.1007/s10147-020-01777-9. Online ahead of print.,"For MFS, apalutamide, darolutamide, and enzalutamide were significantly more effective than placebo, and apalutamide emerged as the best option (P score: 0.8809). ...For PSA-PFS, all three agents were statistically superior to placebo, and apalutamide emerged …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review.,Cancers (Basel). 2020 Sep 9;12(9):E2568. doi: 10.3390/cancers12092568.,"The aim of this systematic review is to describe the evidence about cognitive function in all the randomized trials (RCTs) testing NGHT (abiraterone, enzalutamide, apalutamide, darolutamide). ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide and Overall Survival in Prostate Cancer.,Eur Urol. 2020 Sep 6:S0302-2838(20)30628-X. doi: 10.1016/j.eururo.2020.08.011. Online ahead of print.,Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo arm including 59 patients who received apalutamide after crossover. ...CONCLUSIONS: Extension of OS with apalutamide compared …
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.,Cancer Cell. 2020 Aug 25:S1535-6108(20)30414-1. doi: 10.1016/j.ccell.2020.08.003. Online ahead of print.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.,Future Oncol. 2020 Sep 4. doi: 10.2217/fon-2020-0557. Online ahead of print.,"Apalutamide, a next-generation androgen receptor inhibitor, has recently been shown to provide an added survival benefit in the treatment of mCSPC and consequently approved for this indication. This review summarizes the body of evidence with regards to the preclinical act …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.,BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.,"Most (85.7%) skin rash occurred within 4 months of apalutamide initiation and resolved in a median time of 1 month following the use of antihistamines, topical or systemic corticosteroids, with/without apalutamide dose interruptions/reductions. ...There is a potenti …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair.,Cancers (Basel). 2020 Aug 31;12(9):E2467. doi: 10.3390/cancers12092467.,"Here, we evaluated the potential radiosensitizing effect of the second-generation antiandrogens abiraterone acetate, apalutamide and enzalutamide. (2) Methods: Cell proliferation and agarose-colony forming assay were used to measure the effect on survival. ...These finding …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.,J Natl Cancer Inst. 2020 Aug 28:djaa134. doi: 10.1093/jnci/djaa134. Online ahead of print.,"METHODS: We assessed consistency in AE reporting, AE risk in placebo arms, and methodology used for risk estimates and quantification of statistical uncertainty in randomized placebo-controlled phase 3 trials of apalutamide, enzalutamide and darolutamide in advanced prosta …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.,Can Urol Assoc J. 2020 Aug 18. doi: 10.5489/cuaj.6779. Online ahead of print.,"Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.,Radiol Med. 2020 Aug 27. doi: 10.1007/s11547-020-01264-1. Online ahead of print.,"CONCLUSION: Our survey established the prescription attitude of ADT and new hormonal agents (abiraterone, enzalutamide, apalutamide) by Italian Radiation Oncologists and highlighted the importance of expertise in global PC management...."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.",Cancer Treat Res Commun. 2020 Aug 12;25:100205. doi: 10.1016/j.ctarc.2020.100205. Online ahead of print.,"Since 2018, apalutamide, darolutamide, and enzalutamide have been approved for the treatment of men with non-metastatic castration-resistant prostate cancer (M0CRPC). ...Based on these results, apalutamide, darolutamide, and enzalutamide can now be considered the st …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling.,JCO Clin Cancer Inform. 2020 Aug;4:691-699. doi: 10.1200/CCI.20.00037.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,The evolving options in metastatic castration-sensitive prostate cancer.,Curr Opin Support Palliat Care. 2020 Sep;14(3):270-275. doi: 10.1097/SPC.0000000000000507.,"RECENT FINDINGS: Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting.,Oncol Ther. 2020 Jun 15. doi: 10.1007/s40487-020-00119-z. Online ahead of print.,"This changed when studies showed that the addition of docetaxel chemotherapy or abiraterone acetate to ADT significantly increases overall survival of patients with mHSPC, followed by more recent evidence showing the efficacy of androgen receptor antagonists, such as enzalutamide …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.,Cancer Cell. 2020 Aug 10;38(2):279-296.e9. doi: 10.1016/j.ccell.2020.06.005. Epub 2020 Jul 16.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Recent developments in the treatment of non-metastatic castration resistant prostate cancer.,Cancer Treat Res Commun. 2020;24:100181. doi: 10.1016/j.ctarc.2020.100181. Epub 2020 May 22.,"Recently enzalutamide, apalutamide, and darolutamide respectively, were tested in this disease setting with metastasis free survival (MFS) as the primary endpoint for each trial. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue.,Clin Genitourin Cancer. 2020 Jun 10:S1558-7673(20)30140-3. doi: 10.1016/j.clgc.2020.06.001. Online ahead of print.,
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.,Expert Opin Investig Drugs. 2019 Aug;28(8):667-673. doi: 10.1080/13543784.2019.1648430. Epub 2019 Jul 30.,"This novel agent is known as Etirinotecan Pegol (EP). EP, like irinotecan, exerts its action through its principal metabolite SN-38. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.,Future Oncol. 2019 Jul;15(19):2211-2225. doi: 10.2217/fon-2019-0180. Epub 2019 May 10.,"The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Ph …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.",Eur J Med Chem. 2018 Oct 5;158:82-90. doi: 10.1016/j.ejmech.2018.08.091. Epub 2018 Aug 31.,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC(50) of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respect …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.,Clin Cancer Res. 2018 Jul 15;24(14):3348-3357. doi: 10.1158/1078-0432.CCR-17-3059. Epub 2018 Apr 4.,Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP).Experimental Design: The BEACON trial treated patients with metastatic bre …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.,Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28.,
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.,Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.,"PURPOSE: Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.,Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.,Etirinotecan pegol (NKTR-102) is a long-acting topoisomerase-I inhibitor. We conducted a single-arm phase II trial to evaluate its efficacy in third-line treatment. ...CONCLUSIONS: Etirinotecan pegol was well tolerated and led to 2 partia …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.,Cancer Chemother Pharmacol. 2017 Dec;80(6):1161-1169. doi: 10.1007/s00280-017-3438-y. Epub 2017 Oct 17.,PURPOSE: Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.",Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.,OBJECTIVE: Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.,Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13.,"Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.,Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.,"Although the primary end-point was not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established etirinotecan pegol, a long-acting topoisomerase-1 (TOP1) inhibitor, as a promising therapeutic for patients with advanced/metastatic br …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.,Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30.,PURPOSE: The relationship between incidences of neutropenia and 10-hydroxy-7-ethyl camptothecin (SN38) exposure was explored using SN38 pharmacokinetic and neutrophil count data from toxicology studies of etirinotecan pegol (EP) and irinotecan in beagle dogs. ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.",Springerplus. 2016 Jul 8;5(1):1033. doi: 10.1186/s40064-016-2446-4. eCollection 2016.,Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol for the treatment of breast cancer.,Expert Opin Pharmacother. 2016;17(5):727-34. doi: 10.1517/14656566.2016.1154537. Epub 2016 Mar 10.,AREAS COVERED: This review examines etirinotecan pegol as a promising new agent for the treatment of refractory metastatic breast cancer. ...Etirinotecan pegol pharmacology is reviewed in this paper along with safety and efficacy data from preclinical …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.,Crit Rev Oncol Hematol. 2016 Apr;100:74-87. doi: 10.1016/j.critrevonc.2016.01.021. Epub 2016 Jan 23.,"Etirinotecan pegol, comprising irinotecan bound to polyethylene glycol by a biodegradable linker, is a new cytotoxic agent for patients with MBC that has achieved encouraging response rates in phase II studies; it has been further evaluated in the phase III BEACON t …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.",Lancet Oncol. 2015 Nov;16(15):1556-1568. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.,"Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but reduces the toxicity of, SN38 (the active metabolite of irinotecan). ...METHODS: In this open-label, multicentre, randomised phase 3 study (BEACON; BrEAst Cancer Outcomes wi …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.,BMC Cancer. 2015 Oct 13;15:685. doi: 10.1186/s12885-015-1672-4.,Treatment with NKTR-102 extended survival time (from 35 days to 74 days) and increased overall survival for NKTR-102 low dose (30 % mice) and NKTR-102 high dose (50 % mice). Tumor burden decreased (37 % with 10 mg/kg NKTR-102 …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.,Future Oncol. 2015;11(12):1775-89. doi: 10.2217/fon.15.80.,"Thereafter, the potential role and safety profile of etirinotecan pegol is discussed given the results recently released of a Phase III trial comparing this agent to Treatment of Physician's Choice...."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.,J Med Case Rep. 2015 Feb 12;9:5. doi: 10.1186/1752-1947-9-5.,"To the best of our knowledge, this is the first case report of an impressive iterative response to pegylated irinotecan NKTR-102 in metastatic breast cancer. ...The results of the current phase III trials of pegylated irinotecan NKTR-102 are eagerly aw …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.,J Neurooncol. 2015 Jun;123(2):277-82. doi: 10.1007/s11060-015-1795-0. Epub 2015 May 3.,Etirinotecan pegol (EP) is the first long-acting topoisomerase-I inhibitor designed to concentrate in and provide continuous tumor exposure throughout the entire chemotherapy cycle. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.,PLoS One. 2020 Sep 22;15(9):e0238807. doi: 10.1371/journal.pone.0238807. eCollection 2020.,"METHODS: Between April 2001 and November 2018, 120 patients with complete remission following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were retrospectively reviewed. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.,Blood. 2020 Sep 21:blood.2020006578. doi: 10.1182/blood.2020006578. Online ahead of print.,"The phase II CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective, B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma ( …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.",Medicine (Baltimore). 2020 Sep 18;99(38):e22238. doi: 10.1097/MD.0000000000022238.,"BACKGROUND: Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma. ...CONCLUSION: Evidently, the conclusion of this study will provide an assessment on whether combined procarbazi …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.,Int J Hematol. 2020 Sep 19. doi: 10.1007/s12185-020-03006-5. Online ahead of print.,"Because her ALL had been identified as BCR-ABL1-like ALL with CCDC88C-PDGFRB fusion, she was treated with imatinib for 2 months accompanied by 2 intrathecal methotrexate therapies, and 1 course of L-asparaginase, vincristine, and prednisolone in an outpatient setting. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Radiosensitization by kinase inhibition revealed by phosphoproteomic analysis of pancreatic cancer cells.,Mol Cell Proteomics. 2020 Jul 10:mcp.RA120.002046. doi: 10.1074/mcp.RA120.002046. Online ahead of print.,Pharmacological inhibition of the kinases FAK by Defactinib and of CHEK1 by Rabusertib showed a statistically significant sensitization to radiation in radioresistant PDAC cells. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.",Clin Lymphoma Myeloma Leuk. 2020 Aug 27:S2152-2650(20)30436-5. doi: 10.1016/j.clml.2020.08.018. Online ahead of print.,"Fifty-four percent of patients were men; 45.6% had advanced stage disease; 82% were treated with ABVD (doxorubicin hydrochloride [adriamycin], bleomycin sulfate, vincristine, and dacarbazine) as frontline therapy; and 70% achieved complete response. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments.,BMC Med Genomics. 2020 Sep 18;13(Suppl 8):111. doi: 10.1186/s12920-020-00759-0.,"Chemotherapeutics included taxanes, bortezomib, vincristine, trastuzumab, letrozole, tipifarnib, temozolomide, busulfan and cyclophosphamide...."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.,Int J Mol Sci. 2020 Sep 16;21(18):E6811. doi: 10.3390/ijms21186811.,"In the present study, we aimed to identify chemoresistance gene expression signatures in vincristine resistant neuroblastoma cells. We found that vincristine-resistant neuroblastoma cells formed larger clones and survived under reduced serum conditions as compared w …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Prognostic Models Integrating Quantitative Parameters from Baseline and Interim Positron Emission Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma: Post-Hoc Analysis from the SAKK38/07 Clinical Trial.,Hematol Oncol. 2020 Sep 18. doi: 10.1002/hon.2805. Online ahead of print.,"We centrally reviewed baseline and interim PET/CT scans of 138 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days (R-CHOP14) in the SAKK38/07 trial (ClinicalTrial.gov identifier: NCT00544219). ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.",Bioorg Chem. 2020 Sep 1;104:104193. doi: 10.1016/j.bioorg.2020.104193. Online ahead of print.,"MBR-60 displays synergistic effects with daunorubicin and vincristine and has a selectivity to tumor cells. In comparison to the apoptotic effects of MBR-60 in BJAB lymphoma cells, the cobalt-free ligand 5 does not influence these cells. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Detection of chemotherapy-resistant patient-derived acute lymphoblastic leukemia clones in murine xenografts using cellular barcodes.,Exp Hematol. 2020 Sep 15:S0301-472X(20)30553-1. doi: 10.1016/j.exphem.2020.09.188. Online ahead of print.,"We transplanted Nod/Scid/Il2Rγ(-/-) (NSG) mice with barcoded patient-derived or SupB15 acute lymphoblastic leukemia (ALL) cells, and assessed clonal responses to dexamethasone, methotrexate and vincristine, longitudinally and across nine anatomical locations. ...At end-sta …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Tumor Supernatant Derived from Hepatocellular Carcinoma Cells Treated with Vincristine Sulfate have Therapeutic Activity.,Eur J Pharm Sci. 2020 Sep 15:105557. doi: 10.1016/j.ejps.2020.105557. Online ahead of print.,"Vincristine sulfate (VCR), a commonly used chemotherapeutic agent, kills cancer cells as well as the normal cells for its cytotoxicity. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.",Br J Haematol. 2020 Sep 18. doi: 10.1111/bjh.17103. Online ahead of print.,"Of all 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.",Mol Med Rep. 2020 Jul 20. doi: 10.3892/mmr.2020.11350. Online ahead of print.,"In addition, CD9 knockdown could suppress cell proliferation, adhesion, migration and invasion, and promote apoptosis and the efficacy of chemotherapeutic drugs (such as vincristine, daunorubicin, cyclophosphamide and dexamethasone) and the tyrosine kinase inhibitor imatin …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.,Mol Med Rep. 2020 Jul 17. doi: 10.3892/mmr.2020.11347. Online ahead of print.,"Downregulation of CREBBP increased the IC50 value of daunorubicin; however, no significant affects were observed on the IC50 values of vincristine and L‑asparaginase. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.,Clin Transl Oncol. 2020 Sep 17. doi: 10.1007/s12094-020-02483-8. Online ahead of print.,"Three databases (Medline via PUBMED, SCOPUS, and Cochrane Library) were searched for studies featuring males aged 13-51-years who underwent chemotherapy for HL using ABVD (Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, etoposide, doxoru …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.,Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546.,"We report survival analyses of 431 patients who received frontline rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for advanced FL, and were randomized to receive consolidative HDT/ASCT. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.,Blood Adv. 2020 Sep 22;4(18):4442-4450. doi: 10.1182/bloodadvances.2020002293.,"Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n = 48) were the most common primary treatments. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.,Cancer Med. 2020 Sep 14. doi: 10.1002/cam4.3448. Online ahead of print.,"All were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), plus rituximab for CD20-positive lymphomas. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.,Cancer Cell. 2020 Jan 13;37(1):3-4. doi: 10.1016/j.ccell.2019.12.009.,"Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,A Case of Resolved Vincristine-Induced Constipation Following Osteopathic Medicine in a Patient With Infantile Fibrosarcoma.,J Am Osteopath Assoc. 2020 Oct 1;120(10):691-695. doi: 10.7556/jaoa.2020.102.,Vincristine-induced constipation is a common side effect in pediatric oncology patients. We report the case of an infant with histologic diagnosis of infantile fibrosarcoma who developed significant constipation because of ongoing vincristine administration. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Primary Pancreatic Large B-Cell Lymphoma Presenting as Acute Pancreatitis.,Cureus. 2020 Aug 6;12(8):e9583. doi: 10.7759/cureus.9583.,"The patient achieved remission after six cycles of rituximab-cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), prednisolone (R-CHOP) chemotherapy...."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Early-stage sugar beet taproot development is characterized by three distinct physiological phases.,Plant Direct. 2020 Aug 1;4(7):e00221. doi: 10.1002/pld3.221. eCollection 2020 Jul.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Emotional Well-Being and Cognitive Function Have Robust Relationship With Physical Frailty in Institutionalized Older Women.,Front Psychol. 2020 Jul 16;11:1568. doi: 10.3389/fpsyg.2020.01568. eCollection 2020.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Immunogenicity of HLA-DR1 and HLA-A2 peptides derived from Leishmania major Gp63 in golden hamsters.,Parasite Immunol. 2020 Aug 1:e12780. doi: 10.1111/pim.12780. Online ahead of print.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review.,Chin Med. 2020 Jul 25;15:75. doi: 10.1186/s13020-020-00356-4. eCollection 2020.,"In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi. ..."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Bevacizumab plus UFT Regimen for Four Patients with Stage Ⅳ Colorectal Cancer Receiving Hemodialysis].,Gan To Kagaku Ryoho. 2020 Jul;47(7):1117-1119.,We present case reports of 4 patients on hemodialysis with Stage Ⅳ colorectal cancer who received regular dose bevacizumab( twice per week)plus a daily dose of UFT chemotherapy. ...It is possible that the bevacizumab plus UFT regimen may be acceptable in patients wi …
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Methodologies for assessing the household food availability in the context of food (in)security: a systematic review.,Cien Saude Colet. 2020 Jul 8;25(7):2677-2685. doi: 10.1590/1413-81232020257.29342018.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Hydrolysis of sweet potato (Ipomoea batatas (L.) Lam.) flour by Candida homilentoma strains: effects of pH and temperature using Central Composite Rotatable Design.,An Acad Bras Cienc. 2020;92(2):e20180410. doi: 10.1590/0001-3765202020180410. Epub 2020 Jul 13.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer.,Clin J Gastroenterol. 2020 Jun 29. doi: 10.1007/s12328-020-01169-6. Online ahead of print.,"The rectal adenocarcinoma was treated with chemotherapy, including 1 cycle of capecitabin plus oxaliplatin (CapeOX), 22 cycles of tegafur/gimeracil/oteracil (S-1) plus irinotecan (IRIS), and 1 cycle of tegafur (UFT) plus calcium folinate (LV). ..."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,"Sulfidation of sea urchin-like zinc oxide nanospheres: Kinetics, mechanisms, and impacts on growth of Escherichia coli.",Sci Total Environ. 2020 Nov 1;741:140415. doi: 10.1016/j.scitotenv.2020.140415. Epub 2020 Jun 22.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Weight Loss After RYGB Is Associated with an Increase in Serum Vitamin D in a Population with Low Prevalence of Hypovitaminosis D at Low Latitude.,Obes Surg. 2020 Jun 18. doi: 10.1007/s11695-020-04780-1. Online ahead of print.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Lethal and sublethal effects of the saline stressor sodium chloride on Chironomus xanthus and Girardia tigrina.,Environ Sci Pollut Res Int. 2020 Sep;27(27):34223-34233. doi: 10.1007/s11356-020-09556-9. Epub 2020 Jun 16.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,The Preoperative Dietary Inflammatory Index Predicts Changes in Cardiometabolic Risk Factors After 12 Months of Roux-en-Y Gastric Bypass.,Obes Surg. 2020 Oct;30(10):3932-3939. doi: 10.1007/s11695-020-04756-1.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,A meta-analysis to assess long-term spatiotemporal changes of benthic coral and macroalgae cover in the Mexican Caribbean.,Sci Rep. 2020 Jun 1;10(1):8897. doi: 10.1038/s41598-020-65801-8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: A Case Report and Review.,Cureus. 2020 Apr 25;12(4):e7828. doi: 10.7759/cureus.7828.,"Systemic fluorouracil agents include not only 5-fluorouracil (5FU), but also capecitabine, tegafur, and uracil/tegafur (UFT). ...Fluorouracil agent-induced DLE lesions occurring after initiating treatment with either systemic 5FU or its prodrugs have been described in 19 i …"
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,The risk of COVID-19 transmission in favelas and slums in Brazil.,Public Health. 2020 Jun;183:42-43. doi: 10.1016/j.puhe.2020.04.042. Epub 2020 May 8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Comments on the Classification of Neotropical Scionini (Tabanidae) with a Description of a New Genus.,Neotrop Entomol. 2020 Jun;49(3):412-419. doi: 10.1007/s13744-020-00767-w. Epub 2020 May 12.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[A Case of Duodenal Cancer with Advanced Lymph Node Metastasis Treated with mFOLFOX6 Preoperative Chemotherapy].,Gan To Kagaku Ryoho. 2020 Apr;47(4):625-627.,"UFT/UZEL supplemental postoperative chemotherapy was administered for 6 months. The patient remained alive, with no remissions 3 years post-surgery...."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,"Yeast in plant phytotelmata: Is there a ""core"" community in different localities of rupestrian savannas of Brazil?",Braz J Microbiol. 2020 Sep;51(3):1209-1218. doi: 10.1007/s42770-020-00286-1. Epub 2020 May 8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].,Gan To Kagaku Ryoho. 2020 Mar;47(3):453-455.,The patient has been receiving adjuvant chemotherapy with oral UFT/UZEL for 6months. No recurrence has been observed for the past 4 months....
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone.,J Orthop Translat. 2020 May 19;24:12-22. doi: 10.1016/j.jot.2020.04.008. eCollection 2020 Sep.,RESULTS: This study demonstrated that inhibition of H-type vessels with defactinib alleviated OA by inhibiting H-type vessel-linked MSCs in subchondral bone. ...THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: Our results provide a mechanistic rationale for the use of defac …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.,Apoptosis. 2020 Aug;25(7-8):535-547. doi: 10.1007/s10495-020-01612-6.,"Combination of CP-31398 and defactinib, a FAK inhibitor, also achieved synergistic inhibitory effects and increased p53 with FAK dephosphorylation levels greater than the single treatment. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Feed‑back loops integrating RELA, SOX18 and FAK mediate the break‑down of the lymph‑endothelial barrier that is triggered by 12(S)‑HETE.",Int J Oncol. 2020 Apr;56(4):1034-1044. doi: 10.3892/ijo.2020.4985. Epub 2020 Feb 13.,"The silencing of a combination of these signalling and executing molecules using siRNA, or pharmacological inhibition with defactinib and Bay11‑7082, extended the mono‑culture experiments to co‑culture settings using HCT116 colon cancer cell spheroids that were placed on t …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Mesothelioma: Hippo pathway as a target, lessons from COMMAND.",Oncotarget. 2019 Jun 18;10(40):3996-3997. doi: 10.18632/oncotarget.27018. eCollection 2019 Jun 18.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.,Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.,Oral defactinib and osimertinib were administered in mice bearing subcutaneous xenografts to evaluate the efficacy of the treatment combination in vivo. ...Combination of PTK2 inhibitor and EGFR-TKI (defactinib and osimertinib) recovered EGFR-TKI sensitivity in the …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.,Lung Cancer. 2020 Jan;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. Epub 2019 Nov 4.,Defactinib (VS-6063) is a selective oral inhibitor of FAK. MATERIALS AND METHODS: Patients with previously treated advanced KRAS mutant NSCLC were prospectively assigned to one of four molecularly defined cohorts based on the presence or absence of TP53 or CD …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.,J Clin Oncol. 2019 Sep 1;37(25):2293-2294. doi: 10.1200/JCO.19.00891. Epub 2019 Jul 22.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Reply to K. Masuda et al.,J Clin Oncol. 2019 Sep 1;37(25):2294-2295. doi: 10.1200/JCO.19.01208. Epub 2019 Jul 22.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.",J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.,RESULTS: Three hundred forty-four patients were randomly assigned to receive either defactinib (n = 173) or placebo (n = 171). ...CONCLUSION: Neither PFS nor OS was improved by defactinib after first-line chemotherapy in patients with merlin-low MPM. Defactinib …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.,Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.,Lung Cancer. 2018 Dec;126:15-24. doi: 10.1016/j.lungcan.2018.10.015. Epub 2018 Oct 16.,"Three inhibitors were more efficient than cisplatin, the drug used as first-line chemotherapy in patients with MPM: verteporfin, a putative YAP inhibitor, defactinib, a FAK inhibitor and NSC668394, an Ezrin inhibitor. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.,J Am Chem Soc. 2018 Dec 12;140(49):17019-17026. doi: 10.1021/jacs.8b08008. Epub 2018 Nov 28.,"Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.,PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018.,"Similarly, our new anti-CD133 antibody enabled detection and quantitation of drug-induced reductions in CD133-positive tumor cells following treatment of SUM149PT triple-negative breast cancer xenograft models with the CSC/focal adhesion kinase (FAK) inhibitor VS-6063 …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.,J Int Med Res. 2018 Apr;46(4):1311-1325. doi: 10.1177/0300060517740807. Epub 2018 Jan 14.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.,Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.,The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models. ...Patient-derived prostate tumor explants cultured with both docetaxel and VS-6063 displayed …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.,Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.,"Then we analyze effects of two small molecule inhibitors PF-573228, and PF-431396, which are dual specificity inhibitors of FAK and proline rich tyrosine kinase 2 (PYK2), as well as VS-6063, another small molecule inhibitor that specifically inhibits FAK but not PYK …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.",J Pharm Biomed Anal. 2018 Feb 5;149:358-364. doi: 10.1016/j.jpba.2017.11.022. Epub 2017 Nov 10.,"A sensitive, specific, selective and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of defactinib in mice plasma using (13)C(3,)(15)N-tofacitinib as an internal standard (I.S.). ...Defactinib was found to be stable under various st …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.,Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.,"Prompted by our observation of a correlation between PTEN loss and FAK phosphorylation in a cohort of patients with stage IV SCC, we evaluated the relevance of PTEN loss in cancer progression as well as the efficacy of a new combined treatment with the pan PI3K inhibitor buparlis …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells.,Stem Cell Reports. 2017 Apr 11;8(4):1005-1017. doi: 10.1016/j.stemcr.2017.02.005. Epub 2017 Mar 9.,"CSC-enriched MM cell subpopulations were identified by an OCT4/SOX2 reporter approach and were characterized by (1) increased resistance to cisplatin, (2) increased sensitivity toward the FAK inhibitor VS-6063 in vitro, and (3) a higher tumor-initiating capacity in …"
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.,Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.,We hypothesized that vaccinating against NY-ESO-1 in patients with MDS receiving decitabine would capitalize upon induced NY-ESO-1 expression in malignant myeloid cells to provoke an NY-ESO-1-specific MDS-directed cytotoxic T-cell immune response.Experimental Design: In a phase I …
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Cancer vaccine shows benefit in solid tumors.,Cancer Discov. 2014 Jul;4(7):OF4. doi: 10.1158/2159-8290.CD-NB2014-072. Epub 2014 May 15.,"In a phase I clinical trial, the cancer vaccine CDX-1401 was well tolerated in 45 patients with solid tumors and produced some immune responses...."
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.,Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.,"CDX-1401 is a vaccine composed of a human mAb specific for DEC-205 fused to the full-length tumor antigen NY-ESO-1. This phase 1 trial assessed the safety, immunogenicity, and clinical activity of escalating doses of CDX-1401 with the Toll-like recepto …"
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,CDX-1401 combined with TLR agonist: positive phase 1 results.,Hum Vaccin Immunother. 2012 Dec 1;8(12):1742.,
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Two therapeutic HPV vaccine candidates successful in phase 1.,Hum Vaccin Immunother. 2012 Dec 1;8(12):1741. doi: 10.4161/hv.23373.,Two therapeutic HPV vaccine candidates successful in phase 1 Flu shot may prevent heart attacks and stroke CDX-1401 combined with TLR agonist: Positive phase 1 results Three MRSA vaccines in early clincial trials Ovarian cancer vaccine candidate DPX-Survivac: Positi …
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.",EBioMedicine. 2020 Jul 7:102844. doi: 10.1016/j.ebiom.2020.102844. Online ahead of print.,"Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or placebo once daily for 5 days every 4 weeks for 3 cycles. Primary outcome was change from baseline in Treg percentage of CD4(+) T cells (%Tregs) following a first cycle. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.",Wellcome Open Res. 2020 Mar 20;5:49. doi: 10.12688/wellcomeopenres.15697.1. eCollection 2020.,"A total of 45 participants will be randomised in a 2:1 ratio to receive either ultra-low dose IL-2 (aldesleukin), at a dose of 0.2 x 10 (6) IU/m (2) twice-weekly, given subcutaneously, or placebo, for 6 months. ...The secondary objectives are: 1) to assess the efficacy of …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Systemic Therapies for Advanced Melanoma.,Dermatol Clin. 2019 Oct;37(4):409-423. doi: 10.1016/j.det.2019.05.001. Epub 2019 Jul 10.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.",J Clin Oncol. 2019 Oct 20;37(30):2759-2768. doi: 10.1200/JCO.18.02424. Epub 2019 Aug 13.,"Treatment consisted of autologous genetically engineered T cells expressing a T-cell receptor directed against HPV16 E6 (E6 T-cell receptor T cells), a conditioning regimen, and systemic aldesleukin. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.,Eur J Cancer. 2019 Jul;115:61-67. doi: 10.1016/j.ejca.2019.03.023. Epub 2019 May 17.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"GOF/LOF knowledge inference with tensor decomposition in support of high order link discovery for gene, mutation and disease.",Math Biosci Eng. 2019 Feb 20;16(3):1376-1391. doi: 10.3934/mbe.2019067.,"At the end, a case study reproducing two disease-gene-drug links(Myelodysplatic Syndromes-IL2RA-Aldesleukin, Lymphoma- IL2RA-Aldesleukin) presented the feasibility of our prediction model for drug repurposing...."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.,J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.,METHODS: Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the PROCLAIM(SM) registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk criteria. ...
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.,Cancer Discov. 2020 Jan;10(1):20-22. doi: 10.1158/2159-8290.CD-19-1255.,Hallin and colleagues demonstrate the preclinical activity of the KRAS(G12C)-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. ...
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.,Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. Epub 2018 Dec 5.,Cell infusion was preceded by a lymphocyte-depleting conditioning regimen and followed by systemic high-dose aldesleukin. RESULTS: Objective tumor responses occurred in 5 of 18 (28%) patients in the cervical cancer cohort and 2 of 11 (18%) patients in the noncervical cance …
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.,JCI Insight. 2018 Oct 4;3(19):e99306. doi: 10.1172/jci.insight.99306.,"Using a response-adaptive design, we aimed to determine the optimal regimen of aldesleukin (recombinant human IL-2) to physiologically enhance Tregs while limiting expansion of Teffs. ...CONCLUSIONS: Using a response-adaptive design, aldesleukin treatment can be opt …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial.",BMJ Open. 2018 Sep 17;8(9):e022452. doi: 10.1136/bmjopen-2018-022452.,"Aldesleukin is a human recombinant form of IL-2 that has been used therapeutically in several autoimmune diseases. However, its safety and efficacy is unknown in the setting of coronary artery disease. ...The primary endpoint is safety and tolerability of aldesleukin …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Aldesleukin.,2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Aldesleukin is a recombinant form of human interleukin-2, a cytokine that stimulates the proliferation and maturation of T cells, which is used in immune therapy of renal cell cancer and malignant melanoma. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.,Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.,Acta Oncol. 2018 May;57(5):589-594. doi: 10.1080/0284186X.2018.1433324. Epub 2018 Feb 2.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.,Gynecol Oncol Rep. 2017 Sep 25;22:43-44. doi: 10.1016/j.gore.2017.09.009. eCollection 2017 Nov.,•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity....
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.,Wellcome Open Res. 2017 Oct 5;2:28. doi: 10.12688/wellcomeopenres.11300.3. eCollection 2017.,"To differentiate between the immune response to norovirus and to control for the administration of a single dose of aldesleukin (recombinant interleukin-2, rIL-2) alone, samples from five non-infected participants administered similar doses were analysed in parallel. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.",Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases.",Clin Exp Immunol. 2017 Jun;188(3):394-411. doi: 10.1111/cei.12940. Epub 2017 Mar 20.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,[Clinical Significance of the Balanceshift of Th1 and Th2 Type Cytokines in Patients with Primary Immune Thrombocytopenic Purpura Detected by Cytometric Bead Array].,Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1846-1849. doi: 10.7534/j.issn.1009-2137.2016.06.042.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.,Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.,Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.,"The previously published ""SELECT"" trial of high-dose aldesleukin (HD-IL2) for metastatic renal cell carcinoma resulted in an objective response rate of 25%. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Novel approach to accurately predict bond strength and ligand lability in platinum-based anticancer drugs.,Dalton Trans. 2020 Sep 22;49(36):12632-12642. doi: 10.1039/d0dt02552f.,"In a second stage, we apply the IBSI score to a panel of eleven case studies, comprising mostly antineoplastic agents, such as cisplatin, carboplatin, lobaplatin etc., in order to quantify the coordinate bond strength of the ligands, providing insights about the hydrolysis …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer.,J BUON. 2020 May-Jun;25(3):1490-1496.,PURPOSE: To compare the efficacy and safety of etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer (SCLC). METHODS: A total of 98 extensive-stage SCLC patients treated at the Oncology Department from March 2 …
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer.,Oncol Lett. 2020 Sep;20(3):2493-2498. doi: 10.3892/ol.2020.11765. Epub 2020 Jun 24.,"A total of 38 liver cancer patients in the combined treatment group were treated with lobaplatin-TACE combined with radioactive I-125 seed implantation, while 45 patients in the TACE group were treated only with lobaplatin-TACE. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles.,Cancer Manag Res. 2020 Jun 29;12:5141-5146. doi: 10.2147/CMAR.S249838. eCollection 2020.,OBJECTIVE: This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. ...CONCLUSION: Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients a …
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.,Lung Cancer. 2020 Aug;146:290-296. doi: 10.1016/j.lungcan.2020.06.010. Epub 2020 Jun 20.,"The tumor-feeding arteries were detected on angiography, and chemotherapeutic agents (gemcitabine 1000 mg/m(2) + lobaplatin 30 mg/m(2)) were then administered via arterial infusion. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.,Int J Oncol. 2020 Sep;57(3):697-706. doi: 10.3892/ijo.2020.5085. Epub 2020 Jun 22.,"High concentrations of carboplatin and lobaplatin markedly inhibited Y79 RB cell proliferation in vitro. In addition, the lobaplatin group exhibited higher proportions of early‑stage apoptotic cells than the carboplatin group, while no significant differences in the …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization.,Cell Mol Biol (Noisy-le-grand). 2020 Jun 5;66(3):48-51.,"Patients in the research group adopted the TACE in combination with lobaplatin, while those in the control group took cisplatin instead in combination with TACE. ...TACE is a promising strategy for the treatment of primary carcinoma of the liver, while lobaplatin, a …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma.",Biochem Pharmacol. 2020 Jul;177:114023. doi: 10.1016/j.bcp.2020.114023. Epub 2020 May 13.,"However, the anti-NPC mechanism of lobaplatin remains largely unknown. In present study, 50% inhibiting concentration (IC50) of lobaplatin for NPC cells is found to be similar to that of cisplatin. 10 μM and 20 μM lobaplatin caused obvious gasdermin-E (GSDME) …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.,Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020.,"Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903.,Xenobiotica. 2020 Aug;50(8):980-987. doi: 10.1080/00498254.2020.1728421. Epub 2020 Feb 19.,"LLC-1903, a novel anticancer compound, was synthesized by optimizing the structure, which was derived from altering the leaving group of lobaplatin. ...The plasma level of LLC-1903 is only half of that of lobaplatin (p < 0.01) which could be the direct result of …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,[Risk factor analysis for perineal incision complications after abdominoperineal resection in elderly patients with rectal cancer].,Zhonghua Zhong Liu Za Zhi. 2020 Jan 23;42(1):65-69. doi: 10.3760/cma.j.issn.0253-3766.2020.01.010.,"The result of univariate analysis showed that, the occurrence of perineal incision complications was associated with serum albumin level < 35g/L (χ(2)=4.860, P=0.027), intraperitoneal chemotherapy with fluorouracil sustained release/lobaplatin rinse (χ(2)=8.827, P=0.003 …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Retrospective study of TACE in the treatment of lobaplatin-induced thrombocytopenia in primary hepatocellular carcinoma.,J BUON. 2019 Nov-Dec;24(6):2385-2393.,"The number of first-time users of lobaplatin reached 128, the second-time users reached 417, the third-time and above users 239. ...The level of post-intervention thrombocytopenia was not correlated with the cycles of lobaplatin use. The initial thrombocytopenia was …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.,Medicine (Baltimore). 2019 Dec;98(52):e18513. doi: 10.1097/MD.0000000000018513.,"METHODS: Patients with rMBC received ≥2 cycles (21 days each) of either docetaxel and lobaplatin (DL; n = 21), or docetaxel and gemcitabine (DG; n = 22). ...Patients in DL and DG were also given, respectively, 35 mg/m intravenous lobaplatin (day 2) or 1000 mg/m intr …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.",Thorac Cancer. 2020 Feb;11(2):456-460. doi: 10.1111/1759-7714.13286. Epub 2019 Dec 22.,"The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and bevacizumab. This is the first report of a novel mutation type EGFR-ANXA2, as well as double EGFR fusion mutations in advanced lung adenocarcinoma. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Corrigendum to ""Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro"" [Biomed. Pharmacother. 69 (2015) 402-408].",Biomed Pharmacother. 2019 Dec;120:109511. doi: 10.1016/j.biopha.2019.109511. Epub 2019 Oct 16.,
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Endometrial carcinoma complicated by malignant pericardial effusion: A case report on the therapeutic regimen.,Medicine (Baltimore). 2019 Oct;98(42):e17584. doi: 10.1097/MD.0000000000017584.,"INTERVENTIONS: In addition to cisplatin instilled into the pericardial space, for systemic chemotherapy, we chose that gemcitabine and lobaplatin regimen be preferred. ...When this happens, we recommend ultrasound-guided pericardial puncture and the pericardial injection o …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin promotes (125)I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2α-ATF4-CHOP pathway.,Cell Death Dis. 2019 Oct 3;10(10):744. doi: 10.1038/s41419-019-1918-1.,We investigated the mechanism underlying the effect of a combination treatment of (125)I radioactive seed implantation and lobaplatin (LBP) in hepatocellular carcinoma. ...
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.",Int J Hyperthermia. 2019;36(1):841-853. doi: 10.1080/02656736.2019.1646927.,"Results: TACE procedures were performed using lobaplatin (20-50 mg), epirubicin (30-60 mg), lipiodol (5-25 mL) and gelatin sponge particles (350-560 μm). ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer.,Front Oncol. 2019 Jul 24;9:538. doi: 10.3389/fonc.2019.00538. eCollection 2019.,"Lobaplatin (LBP), a third-generation platinum anti-neoplastic agent, has shown an improved efficacy. This study is aimed to investigate the mechanisms of LBP-induced apoptosis in the A549 p53 wild-type cell line. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer.,Onco Targets Ther. 2019 Jun 21;12:4849-4857. doi: 10.2147/OTT.S192373. eCollection 2019.,OBJECTIVE: To study the efficacy and adverse reactions of lobaplatin combined with other chemotherapy drugs in the treatment of metastatic breast cancer. ...CONCLUSION: Lobaplatin-based regimen chemotherapy for advanced metastatic breast cancer patients is effective …
2020-09-23T05:56:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ501&sort=date&size=20,Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.,J Control Release. 2015 Feb 28;200:201-11. doi: 10.1016/j.jconrel.2014.12.027. Epub 2014 Dec 24.,"Pre-clinical and clinical use of β-lap (clinical form, ARQ501 or 761) is hampered by poor pharmacokinetics and toxicity due to hemolytic anemia. ..."
2020-09-23T05:56:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ501&sort=date&size=20,Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.,Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.,"Improving patient outcome by personalized therapy involves a thorough understanding of an agent's mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme NAD(P)H:q …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,HSP70i is a critical component of the immune response leading to vitiligo.,Pigment Cell Melanoma Res. 2012 Jan;25(1):88-98. doi: 10.1111/j.1755-148X.2011.00916.x. Epub 2011 Nov 14.,"HSP70i and other stress proteins have been used in anti-tumor vaccines. This begs the question whether HSP70i plays a unique role in immune activation. ...By contrast, depigmentation proceeded without interruption in mice lacking a tissue-specific constitutive isoform of …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen.,J Immunol. 2010 Jun 1;184(11):6309-19. doi: 10.4049/jimmunol.0903891. Epub 2010 May 3.,"., gp100) and large stress proteins (e.g., hsp110 and grp170) with exceptional Ag-holding capabilities augment potent tumor protective immunity. ...Both hsp110 and grp170 readily formed complexes with antigenic peptides under physiologic conditions, and the peptide …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.,Cancer Res. 2005 Mar 1;65(5):2009-17. doi: 10.1158/0008-5472.CAN-04-3216.,"We have reported that i.d. injection of plasmids encoding hsp70 and a suicide gene transcriptionally targeted to melanocytes generates specific proinflammatory killing of melanocytes. ...In suboptimal protocols, the T cell response selected B16 variants, which grow extreme …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.,ACS Cent Sci. 2020 Aug 26;6(8):1367-1375. doi: 10.1021/acscentsci.0c00411. Epub 2020 Jul 8.,"LC-2 covalently binds KRAS(G12C) with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS(G12C) degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS(G12C) cell lines. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Inhibition of RAS: proven and potential vulnerabilities.,Biochem Soc Trans. 2020 Sep 1:BST20190023. doi: 10.1042/BST20190023. Online ahead of print.,"Building on this success, several groups have developed similar compounds that selectively target KRAS(G12C), with AMG510 and MRTX849 the first to advance to clinical trials. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,KRAS: From undruggable to a druggable Cancer Target.,Cancer Treat Rev. 2020 Sep;89:102070. doi: 10.1016/j.ctrv.2020.102070. Epub 2020 Jul 15.,"Recently, several small molecules (AMG510, MRTX849, JNJ-74699157, and LY3499446) have been developed to specifically target K-RAS G12C. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Hitting KRAS When It's Down.,J Med Chem. 2020 Jul 9;63(13):6677-6678. doi: 10.1021/acs.jmedchem.0c00785. Epub 2020 Jun 22.,"MRTX849 is one such clinical candidate with promising initial results in patients harboring the mutation. The impressive optimization story of MRTX849 highlights challenges and solutions in the development of covalent drugs, including the use of an α-fluoroacrylamid …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer.",J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6.,"The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRAS(G12C) is described...."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.,J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7.,"MRTX849 was recently identified as a potent, selective and covalent KRAS(G12C) inhibitor that possesses favourable drug-like properties. MRTX849 selectively modifies the mutant cysteine residue in GDP-bound KRAS(G12C) and inhibits GTP-loading and downstream KRAS-dep …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?",Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23.,"Both AMG 510 from Amgen and MRTX849 from Mirati Therapeutics covalently binds to KRAS(G12C) at the cysteine at residue 12, keeping KRAS(G12C) in its inactive GDP-bound state and inhibiting KRAS-dependent signaling. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.,Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.,"MRTX849 was identified as a potent, selective, and covalent KRAS(G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS(G12C), and inhibits KRAS-dependent signaling. ...Combinations of MRTX849 with age …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,[The importance of efflux systems in antibiotic resistance and efflux pump inhibitors in the management of resistance].,Mikrobiyol Bul. 2015 Apr;49(2):278-91. doi: 10.5578/mb.8964.,"There are some compounds known to inhibit bacterial pump systems, such as phenyl-arginine beta naphthylamide (PAβN), INF271, INF55, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), reserpine, 1-(1-naphthylmethyl)-piperazine (NMP), biricodar, timcodar, verapamil, milbemyci …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.,Biochem Pharmacol. 2013 Apr 15;85(8):1057-65. doi: 10.1016/j.bcp.2013.01.015. Epub 2013 Jan 24.,"The addition of either tamoxifen, VX-710, verapamil, or cyclosporin A, antagonists of P-gp, enhanced C6-ceramide cytotoxicity in all cell lines. ..."
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.,Exp Cell Res. 2011 Jul 15;317(12):1736-45. doi: 10.1016/j.yexcr.2011.03.004. Epub 2011 Mar 21.,"For example, C6-cer, VX-710 (Biricodar), and cyclosporin A (cyc A) exposure resulted in viabilities of ~90% of control; however, C6-cer/VX-710 and C6-cer/cyc A additions were synergistic and resulted in viabilities of 22% and 17%, respectively. …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux.,Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):157-75. doi: 10.2174/157489106777452692.,"Apart from (i) a peptidomimetic inhibitor of Mex pumps in Pseudomonas aeruginosa (MC-04,124), for which efficacy was evaluated in animal models, and (ii) a piperidinecarboxylic acid inhibitor of fluoroquinolone efflux in Gram-positive (VX-710), which was safely admi …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37.,"[111In]-DOTA-cG250, [131I]-Metuximab injection, [177Lu]-DOTA-cG250; Anatumomab mafenatox, AP-12009; BIBW-2992, Biricodar dicitrate; Cediranib, Cilengitide, Clevidipine, CNTO-528, CNTO-95, CP-870893; Disufenton sodium, DNK-333A; Ecallantide, Enzastaurin hydrochloride, Etrav …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.,Cancer. 2007 Mar 1;109(5):924-32. doi: 10.1002/cncr.22492.,MDR represents an obstacle to successful chemotherapy treatment and is reversible in Pgp- or MRP-1-expressing cells by the inhibitor VX-710. ...No correlative (99m)Tc-sestamibi uptake in tumor tissue was observed with the addition of VX-710 in this stu …
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Pharmacological strategies for overcoming multidrug resistance.,Curr Drug Targets. 2006 Jul;7(7):861-79. doi: 10.2174/138945006777709593.,"Clinical trials with third generation modulators (e.g. biricodar, zosuquidar, and laniquidar) specifically developed for MDR reversal are ongoing. ..."
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Approaches to multidrug resistance reversal.,Expert Opin Investig Drugs. 1998 Jun;7(6):929-39. doi: 10.1517/13543784.7.6.929.,"Drugs that have clearly shown a potential for sensitisation of resistant cancers with acceptable toxicity include dexverapamil one of the two enantiomers constituting verapamil, valspodar (PSC-833), an analogue of cyclosporine A, and original compounds, named VX-710 …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Immunosuppressors and reversion of multidrug-resistance.,Crit Rev Oncol Hematol. 2005 Oct;56(1):61-70. doi: 10.1016/j.critrevonc.2004.12.010.,
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Thyroid hormone export from cells: contribution of P-glycoprotein.,J Endocrinol. 2005 Apr;185(1):93-8. doi: 10.1677/joe.1.06096.,"We compared the transport of 125I-T3 in MDCKII cells that had been transfected with mdr1 cDNA (MDCKII-MDR) versus wild-type MDCKII cells (MDCKII), and examined the effect of conventional (verapamil and nitrendipine) and specific MDR inhibitors (VX 853 and VX 710 …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853).,Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6. doi: 10.1128/AAC.48.11.4171-4176.2004.,"Based on this precedent, two novel mammalian multiple drug resistance inhibitors, biricodar (VX-710) and timcodar (VX-853), were evaluated for activity in a variety of bacteria. ...Similar to reserpine, VX-710 and VX-853 directly b …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.",Clin Cancer Res. 2004 Mar 1;10(5):1826-34. doi: 10.1158/1078-0432.ccr-0914-3.,PURPOSE: The pipecolinate derivative VX-710 (biricodar; Incel) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1); we studied its activity against the third multidrug resistance (MDR)-associated drug efflux p …
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40.,"This issue focuses on the following selection of drugs: 2F5, 2G12, abetimus sodium, ABI-007, adalimumab, adefovir dipivoxil, AE-941, alefacept, altropane, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminopterin, anakinra, aprinocarsen sodium, atazanavir, …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide.,Cancer Res. 2003 May 15;63(10):2492-8.,"Treating the cells with leukotriene D4, a known MRP1 substrate, or VX-710, an MRP1 modulator, restored flutamide and hydroxyflutamide accumulation. ..."
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.",Cancer Chemother Pharmacol. 2003 Apr;51(4):297-305. doi: 10.1007/s00280-003-0573-4. Epub 2003 Mar 13.,"PURPOSE: VX-710 (biricodar, Incel) restores drug sensitivity to cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP1). ...VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 mic …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.,Cancer Control. 2003 Mar-Apr;10(2):159-65. doi: 10.1177/107327480301000207.,"RESULTS: First-generation agents (eg, cyclosporin, verapamil) were limited by unacceptable toxicity, whereas second-generation agents (eg, valspodar, biricodar) had better tolerability but were confounded by unpredictable pharmacokinetic interactions and interactions with …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Multidrug resistance: can new drugs help chemotherapy score against cancer?,J Natl Cancer Inst. 2003 Feb 19;95(4):255-7. doi: 10.1093/jnci/95.4.255.,
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.",Gynecol Oncol. 2002 Sep;86(3):302-10. doi: 10.1006/gyno.2002.6762.,"PURPOSE: Incel (biricodar, VX-710) restores drug sensitivity to P-glycoprotein (MDR1) and multidrug-resistance-associated protein (MRP1) expressing cells. ...Patients received 80 mg/m(2) paclitaxel over 3 h starting 4 h after initiation of a 24-h continuous i …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Biricodar. Vertex Pharmaceuticals.,Curr Opin Investig Drugs. 2002 May;3(5):818-23.,"By March 2000, Vertex was the sole developer of biricodar, as an agreement made in 1996 with BioChem Pharma (now Shire Pharmaceuticals), for the development and marketing of biricodar in Canada was terminated. Biricodar is the free base compound, which also h …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Reversal of multidrug resistance: lessons from clinical oncology.,"Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5.",
